data_2n9c_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n9c _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 74.040000000000006 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.319999999999993 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 71.409999999999997 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.430000000000007 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.109999999999999 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.349999999999994 110.913 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 74.030000000000001 111.162 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 75.200000000000003 111.148 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 72.409999999999997 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.100000000000001 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.239999999999995 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.129999999999995 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.530000000000001 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 62.439999999999998 111.125 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 73.340000000000003 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.519999999999996 110.899 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.130000000000003 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.310000000000002 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.030000000000001 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.420000000000002 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.409999999999997 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 75.430000000000007 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.150000000000006 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 72.230000000000004 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.109999999999999 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.439999999999998 110.943 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.150000000000006 111.132 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.409999999999997 111.177 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.349999999999994 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.310000000000002 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 72.510000000000005 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.329999999999998 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.530000000000001 111.123 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.210000000000001 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 75.540000000000006 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.430000000000007 110.825 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.340000000000003 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 74.400000000000006 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.130000000000003 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 73.299999999999997 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 74.040000000000006 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.040000000000006 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 71.439999999999998 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 74.230000000000004 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.329999999999998 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 73.219999999999999 111.1 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.530000000000001 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 51.439999999999998 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 63.310000000000002 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.040000000000006 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.420000000000002 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 55.310000000000002 111.199 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 74.329999999999998 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.129999999999995 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.129999999999995 110.812 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.340000000000003 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.239999999999995 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 75.349999999999994 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.209999999999994 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.530000000000001 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.439999999999998 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 75.349999999999994 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.140000000000001 110.939 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.239999999999995 111.128 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 75.420000000000002 111.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 71.329999999999998 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 73.299999999999997 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 73.439999999999998 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.150000000000006 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.210000000000001 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 75.209999999999994 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.530000000000001 110.92 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.310000000000002 110.877 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.310000000000002 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.230000000000004 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 73.439999999999998 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.299999999999997 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.549999999999997 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.439999999999998 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.209999999999994 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 73.430000000000007 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 71.349999999999994 110.919 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 75.349999999999994 111.107 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 72.040000000000006 111.106 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.099999999999994 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.040000000000006 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 71.319999999999993 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 75.219999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 64.340000000000003 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 74.409999999999997 111.149 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 71.549999999999997 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.319999999999993 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.310000000000002 110.857 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.420000000000002 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.409999999999997 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.239999999999995 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 75.030000000000001 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 74.519999999999996 111.124 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.329999999999998 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.519999999999996 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 71.450000000000003 110.939 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 73.400000000000006 110.888 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 74.299999999999997 111.16 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 74.519999999999996 111.108 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 75.409999999999997 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.240000000000002 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.200000000000003 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.340000000000003 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 64.099999999999994 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.510000000000005 111.155 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.099999999999994 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.010000000000005 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 55.549999999999997 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.140000000000001 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 74.340000000000003 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.219999999999999 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.120000000000005 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 75.129999999999995 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.239999999999995 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 74.150000000000006 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 73.400000000000006 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 74.099999999999994 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.019999999999996 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 63.409999999999997 111.126 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.329999999999998 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.310000000000002 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 70.129999999999995 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.120000000000005 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.099999999999994 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 74.310000000000002 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.329999999999998 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.030000000000001 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.129999999999995 110.859 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 75.230000000000004 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 65.219999999999999 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 74.109999999999999 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.310000000000002 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.239999999999995 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.310000000000002 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.530000000000001 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 75.450000000000003 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.400000000000006 110.885 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 72.530000000000001 111.109 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.319999999999993 111.113 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.430000000000007 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 73.25 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.439999999999998 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.120000000000005 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.299999999999997 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.540000000000006 111.128 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.519999999999996 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.430000000000007 110.932 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.519999999999996 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.340000000000003 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 74.340000000000003 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.450000000000003 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.230000000000004 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.439999999999998 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 74.519999999999996 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.439999999999998 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 72.239999999999995 110.949 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 74.409999999999997 111.13 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 63.219999999999999 111.163 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 74.219999999999999 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.439999999999998 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.120000000000005 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.340000000000003 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.519999999999996 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.049999999999997 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.450000000000003 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.149999999999999 110.861 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.439999999999998 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.209999999999994 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 74.340000000000003 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 75.420000000000002 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.530000000000001 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.340000000000003 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.019999999999996 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.219999999999999 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 74.230000000000004 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.319999999999993 110.906 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.329999999999998 111.115 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 65.010000000000005 111.109 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.340000000000003 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 64.209999999999994 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.32 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.239999999999995 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.340000000000003 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.319999999999993 111.158 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.140000000000001 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 73.329999999999998 110.923 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.400000000000006 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 64.549999999999997 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.509999999999998 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 75.25 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 71.049999999999997 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 73.200000000000003 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.329999999999998 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.040000000000006 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.530000000000001 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.420000000000002 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 72.25 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 74.400000000000006 111.15 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 64.129999999999995 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 75.340000000000003 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 62.310000000000002 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.430000000000007 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 64.310000000000002 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 74.099999999999994 111.139 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 54.140000000000001 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 75.430000000000007 110.907 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.310000000000002 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.019999999999996 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 73.299999999999997 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 75.5 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.319999999999993 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 74.329999999999998 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.349999999999994 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.230000000000004 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.420000000000002 110.87 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 73.0 111.129 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 75.099999999999994 111.075 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.109999999999999 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.010000000000005 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.219999999999999 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 74.209999999999994 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.310000000000002 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.200000000000003 111.095 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.109999999999999 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.140000000000001 110.913 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.219999999999999 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.409999999999997 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 75.109999999999999 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 73.450000000000003 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 75.140000000000001 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 55.310000000000002 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 72.420000000000002 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 75.510000000000005 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.409999999999997 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.430000000000007 110.894 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.319999999999993 111.12 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 74.129999999999995 111.145 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.219999999999999 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.540000000000006 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 72.0 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 75.540000000000006 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.319999999999993 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.409999999999997 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 71.230000000000004 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 72.140000000000001 110.912 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 61.020000000000003 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 73.200000000000003 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 70.420000000000002 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.540000000000006 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 75.409999999999997 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.439999999999998 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 73.409999999999997 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.420000000000002 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.219999999999999 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 75.439999999999998 110.923 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 74.409999999999997 111.129 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.340000000000003 111.158 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 75.219999999999999 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 70.519999999999996 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 73.439999999999998 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.010000000000005 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 73.310000000000002 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 71.099999999999994 111.126 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 72.409999999999997 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 62.539999999999999 110.83 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.239999999999995 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 73.230000000000004 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.430000000000007 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 72.239999999999995 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.430000000000007 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.040000000000006 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.299999999999997 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.299999999999997 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.430000000000007 110.956 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 71.420000000000002 111.072 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 74.510000000000005 111.109 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 73.409999999999997 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.430000000000007 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 73.239999999999995 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 72.120000000000005 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.240000000000002 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.409999999999997 111.118 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.310000000000002 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 71.540000000000006 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 73.140000000000001 110.911 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 75.409999999999997 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.450000000000003 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 75.409999999999997 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.129999999999995 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 71.230000000000004 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 74.430000000000007 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 73.109999999999999 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.310000000000002 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 63.509999999999998 110.943 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.209999999999994 111.127 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.299999999999997 111.117 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.510000000000005 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.120000000000005 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.130000000000003 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.140000000000001 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 73.230000000000004 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 70.310000000000002 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.519999999999996 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.209999999999994 110.908 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.140000000000001 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.019999999999996 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.129999999999995 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.420000000000002 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.239999999999995 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.349999999999994 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.430000000000007 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 70.239999999999995 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.540000000000006 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 74.540000000000006 110.967 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 74.340000000000003 111.101 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.319999999999993 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 75.329999999999998 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.140000000000001 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 72.109999999999999 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 72.230000000000004 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.510000000000005 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.540000000000006 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.340000000000003 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 75.420000000000002 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 75.310000000000002 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.140000000000001 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 72.25 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.450000000000003 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 71.519999999999996 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.439999999999998 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.109999999999999 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.109999999999999 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 74.310000000000002 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.100000000000001 110.92 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 74.239999999999995 111.114 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.409999999999997 111.144 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 64.409999999999997 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 74.450000000000003 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 72.219999999999999 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.109999999999999 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.439999999999998 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 75.129999999999995 111.105 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.299999999999997 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 74.430000000000007 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 64.530000000000001 110.893 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.409999999999997 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.310000000000002 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 75.420000000000002 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 74.150000000000006 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.329999999999998 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 73.019999999999996 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 75.409999999999997 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 74.049999999999997 110.894 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.530000000000001 111.114 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 63.030000000000001 111.107 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.010000000000005 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.340000000000003 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.420000000000002 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 72.329999999999998 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.109999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.049999999999997 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 44.420000000000002 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 74.439999999999998 110.9 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.420000000000002 110.852 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 74.400000000000006 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 73.329999999999998 111.139 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 75.010000000000005 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 72.099999999999994 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.430000000000007 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 72.049999999999997 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.150000000000006 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 75.049999999999997 110.873 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.349999999999994 111.131 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 73.049999999999997 111.136 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.109999999999999 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 72.409999999999997 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.129999999999995 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 75.230000000000004 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.240000000000002 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 75.239999999999995 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.230000000000004 110.918 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 73.340000000000003 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.150000000000006 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.430000000000007 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.439999999999998 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 73.310000000000002 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.340000000000003 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.230000000000004 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.099999999999994 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 74.230000000000004 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.120000000000005 110.928 179.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 74.299999999999997 111.138 179.841 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.329999999999998 111.117 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 74.340000000000003 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 73.329999999999998 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.350000000000001 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.319999999999993 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.099999999999994 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 72.140000000000001 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.530000000000001 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.319999999999993 110.904 179.997 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.329999999999998 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.340000000000003 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 64.310000000000002 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.420000000000002 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.329999999999998 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 74.420000000000002 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.5 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.310000000000002 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 73.219999999999999 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 74.409999999999997 110.901 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.409999999999997 111.134 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.019999999999996 111.107 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 75.340000000000003 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 74.349999999999994 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.299999999999997 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.230000000000004 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.349999999999994 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 75.099999999999994 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 74.420000000000002 110.893 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 70.120000000000005 110.861 -179.906 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 74.530000000000001 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.399999999999999 111.122 179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.530000000000001 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 75.439999999999998 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 73.400000000000006 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.310000000000002 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 64.439999999999998 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 75.430000000000007 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 61.299999999999997 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 74.219999999999999 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.319999999999993 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 71.129999999999995 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.209999999999994 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.109999999999999 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.420000000000002 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.239999999999995 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.420000000000002 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 74.129999999999995 110.882 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.310000000000002 110.857 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 65.040000000000006 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 63.240000000000002 111.122 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 62.329999999999998 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 62.43 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 72.030000000000001 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.409999999999997 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.319999999999993 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.409999999999997 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.219999999999999 110.87 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 74.400000000000006 111.118 179.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 64.319999999999993 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 72.430000000000007 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.340000000000003 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.019999999999996 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.150000000000006 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.310000000000002 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.409999999999997 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.299999999999997 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 74.219999999999999 110.905 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.030000000000001 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.510000000000005 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 62.200000000000003 111.139 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.420000000000002 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 74.340000000000003 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.439999999999998 111.178 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.129999999999995 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 73.310000000000002 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.239999999999995 110.866 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 72.439999999999998 110.909 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.549999999999997 111.092 179.865 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 73.230000000000004 111.127 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.519999999999996 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 75.319999999999993 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 74.219999999999999 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 74.310000000000002 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.310000000000002 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.319999999999993 111.094 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 73.109999999999999 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.549999999999997 110.854 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.420000000000002 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 75.299999999999997 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 75.0 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 72.230000000000004 110.969 179.905 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 74.040000000000006 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.319999999999993 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 71.409999999999997 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.430000000000007 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.109999999999999 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.349999999999994 110.913 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 74.030000000000001 111.162 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 75.200000000000003 111.148 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 72.409999999999997 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.100000000000001 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.239999999999995 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.129999999999995 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.530000000000001 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 62.439999999999998 111.125 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 73.340000000000003 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.519999999999996 110.899 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.130000000000003 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.310000000000002 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.030000000000001 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.420000000000002 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.409999999999997 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 75.430000000000007 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.150000000000006 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 72.230000000000004 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.109999999999999 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.439999999999998 110.943 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.150000000000006 111.132 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.409999999999997 111.177 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.349999999999994 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.310000000000002 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 72.510000000000005 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.329999999999998 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.530000000000001 111.123 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.210000000000001 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 75.540000000000006 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.430000000000007 110.825 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.340000000000003 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 74.400000000000006 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.130000000000003 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 73.299999999999997 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 74.040000000000006 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.040000000000006 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 71.439999999999998 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 74.230000000000004 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.329999999999998 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 73.219999999999999 111.1 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.530000000000001 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 51.439999999999998 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 63.310000000000002 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.040000000000006 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.420000000000002 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 55.310000000000002 111.199 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 74.329999999999998 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.129999999999995 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.129999999999995 110.812 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.340000000000003 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.239999999999995 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 75.349999999999994 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.209999999999994 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.530000000000001 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.439999999999998 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 75.349999999999994 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.140000000000001 110.939 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.239999999999995 111.128 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 75.420000000000002 111.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 71.329999999999998 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 73.299999999999997 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 73.439999999999998 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.150000000000006 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.210000000000001 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 75.209999999999994 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.530000000000001 110.92 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.310000000000002 110.877 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.310000000000002 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.230000000000004 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 73.439999999999998 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.299999999999997 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.549999999999997 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.439999999999998 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.209999999999994 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 73.430000000000007 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 71.349999999999994 110.919 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 75.349999999999994 111.107 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 72.040000000000006 111.106 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.099999999999994 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.040000000000006 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 71.319999999999993 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 75.219999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 64.340000000000003 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 74.409999999999997 111.149 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 71.549999999999997 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.319999999999993 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.310000000000002 110.857 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.420000000000002 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.409999999999997 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.239999999999995 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 75.030000000000001 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 74.519999999999996 111.124 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.329999999999998 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.519999999999996 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 71.450000000000003 110.939 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 73.400000000000006 110.888 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 74.299999999999997 111.16 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 74.519999999999996 111.108 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 75.409999999999997 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.240000000000002 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.200000000000003 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.340000000000003 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 64.099999999999994 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.510000000000005 111.155 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.099999999999994 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.010000000000005 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 55.549999999999997 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.140000000000001 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 74.340000000000003 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.219999999999999 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.120000000000005 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 75.129999999999995 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.239999999999995 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 74.150000000000006 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 73.400000000000006 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 74.099999999999994 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.019999999999996 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 63.409999999999997 111.126 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.329999999999998 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.310000000000002 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 70.129999999999995 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.120000000000005 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.099999999999994 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 74.310000000000002 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.329999999999998 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.030000000000001 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.129999999999995 110.859 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 75.230000000000004 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 65.219999999999999 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 74.109999999999999 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.310000000000002 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.239999999999995 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.310000000000002 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.530000000000001 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 75.450000000000003 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.400000000000006 110.885 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 72.530000000000001 111.109 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.319999999999993 111.113 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.430000000000007 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 73.25 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.439999999999998 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.120000000000005 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.299999999999997 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 64.540000000000006 111.128 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.519999999999996 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.430000000000007 110.932 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.519999999999996 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.340000000000003 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 74.340000000000003 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.450000000000003 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.230000000000004 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.439999999999998 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 74.519999999999996 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.439999999999998 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 72.239999999999995 110.949 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 74.409999999999997 111.13 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 63.219999999999999 111.163 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 74.219999999999999 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.439999999999998 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.120000000000005 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.340000000000003 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.519999999999996 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.049999999999997 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.450000000000003 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.149999999999999 110.861 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.439999999999998 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.209999999999994 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 74.340000000000003 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 75.420000000000002 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.530000000000001 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.340000000000003 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.019999999999996 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.219999999999999 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 74.230000000000004 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.319999999999993 110.906 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.329999999999998 111.115 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 65.010000000000005 111.109 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.340000000000003 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 64.209999999999994 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.32 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.239999999999995 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.340000000000003 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.319999999999993 111.158 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.140000000000001 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 73.329999999999998 110.923 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.400000000000006 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 64.549999999999997 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.509999999999998 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 75.25 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 71.049999999999997 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 73.200000000000003 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.329999999999998 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.040000000000006 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.530000000000001 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.420000000000002 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 72.25 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 74.400000000000006 111.15 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 64.129999999999995 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 75.340000000000003 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 62.310000000000002 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.430000000000007 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 64.310000000000002 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 74.099999999999994 111.139 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 54.140000000000001 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 75.430000000000007 110.907 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.310000000000002 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.019999999999996 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 73.299999999999997 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 75.5 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.319999999999993 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 74.329999999999998 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.349999999999994 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.230000000000004 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.420000000000002 110.87 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 73.0 111.129 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 75.099999999999994 111.075 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.109999999999999 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.010000000000005 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.219999999999999 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 74.209999999999994 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.310000000000002 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.200000000000003 111.095 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.109999999999999 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.140000000000001 110.913 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.219999999999999 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.409999999999997 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 75.109999999999999 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 73.450000000000003 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 75.140000000000001 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 55.310000000000002 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 72.420000000000002 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 75.510000000000005 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.409999999999997 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.430000000000007 110.894 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.319999999999993 111.12 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 74.129999999999995 111.145 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.219999999999999 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.540000000000006 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 72.0 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 75.540000000000006 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.319999999999993 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.409999999999997 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 71.230000000000004 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 72.140000000000001 110.912 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 61.020000000000003 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 73.200000000000003 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 70.420000000000002 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.540000000000006 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 75.409999999999997 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.439999999999998 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 73.409999999999997 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.420000000000002 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.219999999999999 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 75.439999999999998 110.923 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 74.409999999999997 111.129 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.340000000000003 111.158 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 75.219999999999999 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 70.519999999999996 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 73.439999999999998 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.010000000000005 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 73.310000000000002 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 71.099999999999994 111.126 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 72.409999999999997 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 62.539999999999999 110.83 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.239999999999995 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 73.230000000000004 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.430000000000007 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 72.239999999999995 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.430000000000007 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.040000000000006 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.299999999999997 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.299999999999997 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.430000000000007 110.956 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 71.420000000000002 111.072 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 74.510000000000005 111.109 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 73.409999999999997 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.430000000000007 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 73.239999999999995 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 72.120000000000005 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.240000000000002 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.409999999999997 111.118 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.310000000000002 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 71.540000000000006 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 73.140000000000001 110.911 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 75.409999999999997 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.450000000000003 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 75.409999999999997 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.129999999999995 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 71.230000000000004 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 74.430000000000007 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 73.109999999999999 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.310000000000002 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 63.509999999999998 110.943 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.209999999999994 111.127 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.299999999999997 111.117 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.510000000000005 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.120000000000005 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.130000000000003 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.140000000000001 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 73.230000000000004 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 70.310000000000002 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.519999999999996 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.209999999999994 110.908 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.140000000000001 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.019999999999996 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.129999999999995 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.420000000000002 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.239999999999995 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.349999999999994 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.430000000000007 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 70.239999999999995 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.540000000000006 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 74.540000000000006 110.967 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 74.340000000000003 111.101 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.319999999999993 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 75.329999999999998 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.140000000000001 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 72.109999999999999 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 72.230000000000004 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.510000000000005 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.540000000000006 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.340000000000003 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 75.420000000000002 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 75.310000000000002 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.140000000000001 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 72.25 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.450000000000003 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 71.519999999999996 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.439999999999998 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.109999999999999 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.109999999999999 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 74.310000000000002 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.100000000000001 110.92 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 74.239999999999995 111.114 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.409999999999997 111.144 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 64.409999999999997 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 74.450000000000003 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 72.219999999999999 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.109999999999999 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.439999999999998 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 75.129999999999995 111.105 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.299999999999997 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 74.430000000000007 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 64.530000000000001 110.893 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.409999999999997 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.310000000000002 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 75.420000000000002 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 74.150000000000006 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.329999999999998 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 73.019999999999996 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 75.409999999999997 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 74.049999999999997 110.894 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.530000000000001 111.114 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 63.030000000000001 111.107 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.010000000000005 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.340000000000003 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.420000000000002 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 72.329999999999998 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.109999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.049999999999997 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 44.420000000000002 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 74.439999999999998 110.9 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.420000000000002 110.852 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 74.400000000000006 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 73.329999999999998 111.139 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 75.010000000000005 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 72.099999999999994 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.430000000000007 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 72.049999999999997 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.150000000000006 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 75.049999999999997 110.873 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.349999999999994 111.131 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 73.049999999999997 111.136 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.109999999999999 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 72.409999999999997 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.129999999999995 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 75.230000000000004 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.240000000000002 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 75.239999999999995 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.230000000000004 110.918 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 73.340000000000003 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.150000000000006 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.430000000000007 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.439999999999998 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 73.310000000000002 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.340000000000003 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.230000000000004 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.099999999999994 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 74.230000000000004 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.120000000000005 110.928 179.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 74.299999999999997 111.138 179.841 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.329999999999998 111.117 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 74.340000000000003 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 73.329999999999998 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.350000000000001 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.319999999999993 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.099999999999994 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 72.140000000000001 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.530000000000001 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.319999999999993 110.904 179.997 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.329999999999998 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.340000000000003 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 64.310000000000002 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.420000000000002 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.329999999999998 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 74.420000000000002 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.5 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.310000000000002 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 73.219999999999999 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 74.409999999999997 110.901 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.409999999999997 111.134 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.019999999999996 111.107 179.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 75.340000000000003 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 74.349999999999994 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.299999999999997 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.230000000000004 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.349999999999994 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 75.099999999999994 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 74.420000000000002 110.893 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 70.120000000000005 110.861 -179.906 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 74.530000000000001 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.399999999999999 111.122 179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.530000000000001 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 75.439999999999998 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 73.400000000000006 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.310000000000002 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 64.439999999999998 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 75.430000000000007 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 61.299999999999997 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 74.219999999999999 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.319999999999993 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 71.129999999999995 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.209999999999994 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.109999999999999 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.420000000000002 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.239999999999995 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.420000000000002 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 74.129999999999995 110.882 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.310000000000002 110.857 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 65.040000000000006 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 63.240000000000002 111.122 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 62.329999999999998 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 62.43 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 72.030000000000001 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.409999999999997 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.319999999999993 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.409999999999997 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.219999999999999 110.87 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 74.400000000000006 111.118 179.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 64.319999999999993 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 72.430000000000007 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.340000000000003 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.019999999999996 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.150000000000006 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.310000000000002 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.409999999999997 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.299999999999997 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 74.219999999999999 110.905 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.030000000000001 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.510000000000005 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 62.200000000000003 111.139 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.420000000000002 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 74.340000000000003 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.439999999999998 111.178 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.129999999999995 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 73.310000000000002 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.239999999999995 110.866 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 72.439999999999998 110.909 179.909 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.549999999999997 111.092 179.865 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 73.230000000000004 111.127 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.519999999999996 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 75.319999999999993 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 74.219999999999999 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 74.310000000000002 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.310000000000002 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.319999999999993 111.094 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 73.109999999999999 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.549999999999997 110.854 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.420000000000002 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 75.299999999999997 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 75.0 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 72.230000000000004 110.969 179.905 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 61.31 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.32 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 62.04 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.11 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.495 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.35 110.913 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 72.24 111.162 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.489 HG13 ' HB ' ' A' ' 14' ' ' VAL . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 55.33 111.148 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 65.14 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.1 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.24 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.13 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.53 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.489 ' HB ' HG13 ' A' ' 8' ' ' VAL . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 55.12 111.125 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 72.55 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.449 ' HB2' HG21 ' A' ' 8' ' ' VAL . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.41 110.899 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.13 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.01 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.03 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.42 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.41 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 72.05 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.15 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 71.45 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.11 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.44 110.943 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.15 111.132 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.723 HG11 ' H ' ' A' ' 17' ' ' SER . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.41 111.177 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.35 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.31 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 63.21 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.33 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.406 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.53 111.123 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.21 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 74.52 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.723 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.43 110.825 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.34 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 71.22 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.13 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 72.43 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 53.44 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.04 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 64.53 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 73.12 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.2 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.618 HG13 ' HB ' ' A' ' 14' ' ' VAL . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 63.22 111.1 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.44 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 41.02 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 33.4 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.04 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.42 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.618 ' HB ' HG13 ' A' ' 8' ' ' VAL . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 51.32 111.199 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 72.2 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.13 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.61 ' H ' HG11 ' A' ' 8' ' ' VAL . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.13 110.812 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.34 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.24 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 74.14 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.21 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.53 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.22 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 73.23 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.492 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.14 110.939 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 6' ' ' LEU . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.24 111.128 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.736 HG11 ' H ' ' A' ' 17' ' ' SER . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 65.24 111.14 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 55.43 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 54.13 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 53.13 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.15 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.21 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 53.43 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.408 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.53 110.92 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.736 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 63.31 110.877 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 44.22 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 16' ' ' LYS . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.23 111.131 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 72.12 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.3 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.55 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.44 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.21 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 64.34 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.446 HD12 HG23 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 54.34 110.919 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 HD12 ' A' ' 6' ' ' LEU . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 62.01 111.107 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG13 ' HB ' ' A' ' 14' ' ' VAL . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 44.23 111.106 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 51.11 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.04 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 23.13 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 43.22 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 63.23 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.671 ' HB ' HG13 ' A' ' 8' ' ' VAL . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 44.13 111.149 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 64.42 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.32 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.602 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.31 110.857 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.42 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.41 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 71.41 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.423 HG22 ' HD3' ' A' ' 5' ' ' LYS . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.13 111.124 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.33 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.52 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.423 ' HD3' HG22 ' A' ' 2' ' ' THR . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 64.23 110.939 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.645 HD12 HG23 ' A' ' 7' ' ' VAL . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 70.01 110.888 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.645 HG23 HD12 ' A' ' 6' ' ' LEU . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 72.23 111.16 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 71.31 111.108 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 64.43 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.24 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.2 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.34 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 53.31 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.512 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.51 111.155 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.1 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.01 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 43.32 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.14 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 44.1 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.22 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.12 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 63.23 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.24 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 62.12 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 63.23 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 65.22 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.02 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.62 HG11 ' H ' ' A' ' 17' ' ' SER . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 52.14 111.126 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.24 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.31 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 65.52 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.12 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.1 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 54.25 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.33 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.03 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.62 ' H ' HG11 ' A' ' 8' ' ' VAL . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.13 110.859 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 62.54 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 64.15 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 61.3 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.31 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.24 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.31 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.53 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 71.33 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.497 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.35 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.497 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 63.03 111.109 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.531 HG13 ' HB ' ' A' ' 14' ' ' VAL . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.32 111.113 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.43 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 62.5 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 61.53 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.12 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.12 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.531 ' HB ' HG13 ' A' ' 8' ' ' VAL . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 54.41 111.128 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.52 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.494 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.4 110.932 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.52 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.33 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 71.01 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.45 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.23 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.44 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 31.13 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.42 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 54.14 110.949 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.489 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 64.42 111.13 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.484 HG11 ' HB2' ' A' ' 16' ' ' LYS . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 53.11 111.163 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 72.13 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.44 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.12 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.34 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.52 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.05 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.45 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.484 ' HB2' HG11 ' A' ' 8' ' ' VAL . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.15 110.861 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.21 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 72.53 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 73.53 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.53 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.22 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.02 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.12 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.34 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.49 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.32 110.906 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.49 HG23 ' CD1' ' A' ' 6' ' ' LEU . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.33 111.115 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.678 HG13 ' HB ' ' A' ' 14' ' ' VAL . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 44.33 111.109 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.34 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 63.24 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.1 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.24 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.34 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.678 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.12 111.158 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.14 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.616 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 64.25 110.923 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.4 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 54.22 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.51 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 72.21 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 63.43 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 71.4 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.33 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.04 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.53 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.42 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 65.42 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.683 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 54.25 111.15 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 62.23 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 25.22 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 54.03 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.43 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 62.21 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.683 ' HB ' HG13 ' A' ' 8' ' ' VAL . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 71.12 111.139 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 44.5 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.576 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 72.34 110.907 -179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.31 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.02 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 65.21 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 74.32 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.32 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 64.25 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.35 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.23 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.42 110.87 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 61.22 111.129 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.556 HG13 ' HB ' ' A' ' 14' ' ' VAL . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 53.04 111.075 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.11 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.01 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.22 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 64.31 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.31 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.556 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.2 111.095 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.11 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.444 ' HB2' HG21 ' A' ' 8' ' ' VAL . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.14 110.913 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.22 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.41 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.34 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 64.14 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 70.03 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 54.14 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 63.42 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.41 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.43 110.894 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.32 111.12 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.541 HG11 ' HB2' ' A' ' 16' ' ' LYS . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 73.12 111.145 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.54 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 64.11 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 65.23 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.32 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.41 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 44.54 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 65.41 110.912 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 53.52 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 71.32 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 62.23 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.54 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 73.31 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.44 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 63.35 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.42 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.22 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.513 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 73.13 110.923 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.513 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 50.31 111.129 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.659 HG11 ' H ' ' A' ' 17' ' ' SER . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.158 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 64.22 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 61.53 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 71.54 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.01 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 34.52 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.519 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 61.31 111.126 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 71.31 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.45 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.659 ' H ' HG11 ' A' ' 8' ' ' VAL . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 51.14 110.83 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 72.32 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.33 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 64.5 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.43 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.04 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.3 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.02 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.527 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.43 110.956 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.527 HG23 ' CD1' ' A' ' 6' ' ' LEU . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 54.33 111.072 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.711 HG11 ' H ' ' A' ' 17' ' ' SER . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 70.1 111.109 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 71.21 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.43 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 22.24 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 34.01 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.24 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.472 ' HB ' HG13 ' A' ' 8' ' ' VAL . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.41 111.118 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.31 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 42.1 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.711 ' H ' HG11 ' A' ' 8' ' ' VAL . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 64.1 110.911 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 55.42 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.45 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.13 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 34.03 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 65.44 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 61.52 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.31 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.535 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 62.52 110.943 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.535 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 72.24 111.127 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG11 ' HB2' ' A' ' 16' ' ' LYS . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 53.41 111.117 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.51 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.12 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.13 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.14 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 43.55 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 40.54 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.52 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.651 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.21 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.14 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.02 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.13 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.42 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.24 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.35 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.43 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 65.22 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.01 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 73.13 110.967 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 72.24 111.101 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.32 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 74.23 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.14 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 63.23 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 62.13 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.51 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.54 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.34 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 61.34 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 71.33 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.14 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 71.43 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.45 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 62.54 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.44 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.11 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 70.44 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.514 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.1 110.92 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 72.44 111.114 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.716 HG11 ' H ' ' A' ' 17' ' ' SER . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.15 111.144 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 63.03 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 71.55 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 41.02 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.11 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.44 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.486 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 71.14 111.105 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.14 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 52.22 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.716 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 55.41 110.893 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.41 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 71.35 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 54.53 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 72.31 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.33 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 65.55 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 65.34 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 73.52 110.894 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' CD1' ' A' ' 6' ' ' LEU . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.53 111.114 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.734 HG11 ' H ' ' A' ' 17' ' ' SER . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 62.3 111.107 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 72.52 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.34 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.32 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 64.14 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.11 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.05 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 34.11 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.447 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 64.25 110.9 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.734 ' H ' HG11 ' A' ' 8' ' ' VAL . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.42 110.852 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 73.52 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 16' ' ' LYS . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 61.25 111.139 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 63.51 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.43 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 64.33 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.15 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 74.42 110.873 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.35 111.131 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.694 HG11 ' HB2' ' A' ' 16' ' ' LYS . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 60.02 111.136 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.11 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 70.34 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.13 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 44.33 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.24 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 41.22 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.694 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.03 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 71.4 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.15 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.43 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.11 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 72.14 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.34 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.23 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.487 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.12 110.928 179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.487 HG23 ' CD1' ' A' ' 6' ' ' LEU . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 63.02 111.138 179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.542 HG11 ' HB2' ' A' ' 16' ' ' LYS . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.33 111.117 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 54.32 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 63.24 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.35 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.32 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.1 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 71.42 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.53 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.542 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.32 110.904 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.33 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 62.54 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.42 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.33 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 64.14 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.41 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.31 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 71.54 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.536 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 71.14 110.901 179.896 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.41 111.134 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.631 HG11 ' HB2' ' A' ' 17' ' ' SER . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.02 111.107 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 71.44 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 61.31 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.3 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.23 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.35 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 55.01 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.526 ' O ' HG23 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 71.14 110.893 -179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.631 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 40.12 110.861 -179.906 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 73.12 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 16' ' ' LYS . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.122 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.53 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 71.15 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 65.21 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 63.12 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 74.32 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.05 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' A' ' 17' ' ' SER . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.32 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 54.23 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.21 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.11 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.42 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.24 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.42 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.586 ' O ' HG23 ' A' ' 19' ' ' VAL . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 71.2 110.882 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.542 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.31 110.857 -179.917 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 64.44 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 16' ' ' LYS . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 62.43 111.122 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 60.12 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 61.12 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 61.3 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.41 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.32 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.41 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.51 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 52.32 110.87 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.51 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 73.51 111.118 179.879 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 50.01 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 70.41 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.34 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.02 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.15 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.31 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.41 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.3 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.51 ' O ' HG23 ' A' ' 19' ' ' VAL . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 72.14 110.905 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.03 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 16' ' ' LYS . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 41.11 111.139 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.42 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 42.34 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.432 HG22 ' HD3' ' A' ' 5' ' ' LYS . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.44 111.178 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.13 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 60.34 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' HG22 ' A' ' 2' ' ' THR . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.24 110.866 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.434 HD12 HG23 ' A' ' 7' ' ' VAL . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 33.15 110.909 179.909 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.434 HG23 HD12 ' A' ' 6' ' ' LEU . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.55 111.092 179.865 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 16' ' ' LYS . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 72.21 111.127 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.52 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 43.22 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 73.44 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 63.12 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.31 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.468 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.32 111.094 -179.96 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 53.14 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.489 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.55 110.854 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.42 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 72.45 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 63.1 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.969 179.905 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 61.31 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.32 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 62.04 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.11 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.495 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.35 110.913 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 72.24 111.162 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.489 HG13 ' HB ' ' A' ' 14' ' ' VAL . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 55.33 111.148 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 65.14 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.1 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.24 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.13 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.53 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.489 ' HB ' HG13 ' A' ' 8' ' ' VAL . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 55.12 111.125 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 72.55 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.449 ' HB2' HG21 ' A' ' 8' ' ' VAL . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.41 110.899 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.13 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.01 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.03 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.42 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.41 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 72.05 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.15 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 71.45 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.11 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.44 110.943 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.15 111.132 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.723 HG11 ' H ' ' A' ' 17' ' ' SER . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.41 111.177 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.35 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.31 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 63.21 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.33 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.406 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.53 111.123 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.21 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 74.52 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.723 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.43 110.825 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.34 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 71.22 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.13 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 72.43 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 53.44 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.04 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 64.53 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 73.12 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.2 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.618 HG13 ' HB ' ' A' ' 14' ' ' VAL . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 63.22 111.1 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.44 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 41.02 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 33.4 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.04 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.42 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.618 ' HB ' HG13 ' A' ' 8' ' ' VAL . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 51.32 111.199 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 72.2 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.13 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.61 ' H ' HG11 ' A' ' 8' ' ' VAL . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.13 110.812 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.34 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.24 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 74.14 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.21 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.53 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.22 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 73.23 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.492 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.14 110.939 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 6' ' ' LEU . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.24 111.128 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.736 HG11 ' H ' ' A' ' 17' ' ' SER . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 65.24 111.14 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 55.43 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 54.13 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 53.13 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.15 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.21 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 53.43 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.408 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.53 110.92 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.736 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 63.31 110.877 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 44.22 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 16' ' ' LYS . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.23 111.131 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 72.12 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.3 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.55 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.44 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.21 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 64.34 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.446 HD12 HG23 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 54.34 110.919 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 HD12 ' A' ' 6' ' ' LEU . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 62.01 111.107 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG13 ' HB ' ' A' ' 14' ' ' VAL . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 44.23 111.106 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 51.11 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.04 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 23.13 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 43.22 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 63.23 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.671 ' HB ' HG13 ' A' ' 8' ' ' VAL . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 44.13 111.149 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 64.42 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.32 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.602 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.31 110.857 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.42 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.41 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 71.41 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.423 HG22 ' HD3' ' A' ' 5' ' ' LYS . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.13 111.124 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.33 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.52 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.423 ' HD3' HG22 ' A' ' 2' ' ' THR . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 64.23 110.939 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.645 HD12 HG23 ' A' ' 7' ' ' VAL . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 70.01 110.888 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.645 HG23 HD12 ' A' ' 6' ' ' LEU . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 72.23 111.16 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 71.31 111.108 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 64.43 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.24 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.2 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.34 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 53.31 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.512 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.51 111.155 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.1 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.01 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 43.32 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.14 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 44.1 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.22 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.12 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 63.23 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.24 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 62.12 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 63.23 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 65.22 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.02 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.62 HG11 ' H ' ' A' ' 17' ' ' SER . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 52.14 111.126 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.24 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.31 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 65.52 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.12 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.1 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 54.25 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.33 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.03 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.62 ' H ' HG11 ' A' ' 8' ' ' VAL . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.13 110.859 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 62.54 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 64.15 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 61.3 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.31 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.24 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.31 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.53 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 71.33 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.497 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.35 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.497 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 63.03 111.109 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.531 HG13 ' HB ' ' A' ' 14' ' ' VAL . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.32 111.113 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.43 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 62.5 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 61.53 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.12 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.12 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.531 ' HB ' HG13 ' A' ' 8' ' ' VAL . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 54.41 111.128 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.52 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.494 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.4 110.932 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.52 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.33 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 71.01 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.45 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.23 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.44 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 31.13 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.42 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 54.14 110.949 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.489 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 64.42 111.13 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.484 HG11 ' HB2' ' A' ' 16' ' ' LYS . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 53.11 111.163 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 72.13 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.44 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.12 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.34 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.52 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.05 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.45 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.484 ' HB2' HG11 ' A' ' 8' ' ' VAL . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.15 110.861 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.21 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 72.53 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 73.53 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.53 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.22 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.02 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.12 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.34 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.49 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.32 110.906 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.49 HG23 ' CD1' ' A' ' 6' ' ' LEU . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.33 111.115 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.678 HG13 ' HB ' ' A' ' 14' ' ' VAL . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 44.33 111.109 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.34 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 63.24 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.1 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.24 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.34 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.678 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.12 111.158 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.14 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.616 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 64.25 110.923 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.4 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 54.22 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.51 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 72.21 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 63.43 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 71.4 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.33 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.04 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.53 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.42 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 65.42 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.683 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 54.25 111.15 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 62.23 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 25.22 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 54.03 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.43 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 62.21 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.683 ' HB ' HG13 ' A' ' 8' ' ' VAL . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 71.12 111.139 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 44.5 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.576 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 72.34 110.907 -179.988 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.31 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.02 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 65.21 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 74.32 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.32 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 64.25 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.35 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.23 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.42 110.87 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 61.22 111.129 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.556 HG13 ' HB ' ' A' ' 14' ' ' VAL . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 53.04 111.075 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.11 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.01 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.22 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 64.31 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.31 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.556 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.2 111.095 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.11 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.444 ' HB2' HG21 ' A' ' 8' ' ' VAL . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.14 110.913 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.22 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.41 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.34 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 64.14 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 70.03 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 54.14 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 63.42 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.41 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.43 110.894 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.32 111.12 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.541 HG11 ' HB2' ' A' ' 16' ' ' LYS . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 73.12 111.145 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.54 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 64.11 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 65.23 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.32 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.41 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 44.54 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 65.41 110.912 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 53.52 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 71.32 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 62.23 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.54 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 73.31 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.44 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 63.35 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.42 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.22 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.513 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 73.13 110.923 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.513 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 50.31 111.129 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.659 HG11 ' H ' ' A' ' 17' ' ' SER . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.158 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 64.22 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 61.53 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 71.54 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.01 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 34.52 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.519 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 61.31 111.126 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 71.31 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.45 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.659 ' H ' HG11 ' A' ' 8' ' ' VAL . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 51.14 110.83 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 72.32 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.33 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 64.5 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.43 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.04 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.3 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.02 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.527 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.43 110.956 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.527 HG23 ' CD1' ' A' ' 6' ' ' LEU . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 54.33 111.072 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.711 HG11 ' H ' ' A' ' 17' ' ' SER . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 70.1 111.109 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 71.21 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.43 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 22.24 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 34.01 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.24 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.472 ' HB ' HG13 ' A' ' 8' ' ' VAL . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.41 111.118 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.31 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 42.1 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.711 ' H ' HG11 ' A' ' 8' ' ' VAL . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 64.1 110.911 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 55.42 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.45 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.13 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 34.03 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 65.44 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 61.52 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.31 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.535 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 62.52 110.943 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.535 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 72.24 111.127 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG11 ' HB2' ' A' ' 16' ' ' LYS . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 53.41 111.117 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.51 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.12 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.13 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.14 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 43.55 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 40.54 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.52 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.651 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.21 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.14 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.02 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.13 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.42 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.24 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.35 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.43 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 65.22 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.01 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 73.13 110.967 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 72.24 111.101 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.32 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 74.23 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.14 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 63.23 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 62.13 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.51 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.54 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.34 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 61.34 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 71.33 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.14 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 71.43 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.45 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 62.54 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.44 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.11 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 70.44 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.514 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.1 110.92 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 72.44 111.114 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.716 HG11 ' H ' ' A' ' 17' ' ' SER . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.15 111.144 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 63.03 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 71.55 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 41.02 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.11 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.44 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.486 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 71.14 111.105 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.14 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 52.22 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.716 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 55.41 110.893 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.41 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 71.35 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 54.53 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 72.31 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.33 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 65.55 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 65.34 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.424 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 73.52 110.894 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' CD1' ' A' ' 6' ' ' LEU . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.53 111.114 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.734 HG11 ' H ' ' A' ' 17' ' ' SER . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 62.3 111.107 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 72.52 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.34 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.32 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 64.14 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.11 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.05 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 34.11 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.447 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 64.25 110.9 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.734 ' H ' HG11 ' A' ' 8' ' ' VAL . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.42 110.852 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 73.52 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 16' ' ' LYS . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 61.25 111.139 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 63.51 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.43 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 64.33 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.15 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 74.42 110.873 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.35 111.131 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.694 HG11 ' HB2' ' A' ' 16' ' ' LYS . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 60.02 111.136 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.11 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 70.34 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.13 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 44.33 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.24 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 41.22 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.694 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.03 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 71.4 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.15 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.43 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.11 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 72.14 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.34 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.23 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.487 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.12 110.928 179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.487 HG23 ' CD1' ' A' ' 6' ' ' LEU . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 63.02 111.138 179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.542 HG11 ' HB2' ' A' ' 16' ' ' LYS . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.33 111.117 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 54.32 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 63.24 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.35 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.32 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.1 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 71.42 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.53 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.542 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.32 110.904 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.33 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 62.54 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.42 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.33 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 64.14 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.41 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.31 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 71.54 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.536 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 71.14 110.901 179.896 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.41 111.134 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.631 HG11 ' HB2' ' A' ' 17' ' ' SER . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.02 111.107 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 71.44 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 61.31 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.3 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.23 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.35 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 55.01 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.526 ' O ' HG23 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 71.14 110.893 -179.951 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.631 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 40.12 110.861 -179.906 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 73.12 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 16' ' ' LYS . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.122 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.53 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 71.15 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 65.21 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 63.12 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 74.32 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.05 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' A' ' 17' ' ' SER . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.32 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 54.23 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.21 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.11 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.42 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.24 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.42 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.586 ' O ' HG23 ' A' ' 19' ' ' VAL . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 71.2 110.882 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.542 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.31 110.857 -179.917 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 64.44 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 16' ' ' LYS . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 62.43 111.122 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 60.12 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 61.12 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 61.3 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.41 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.32 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.41 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.51 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 52.32 110.87 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.51 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 73.51 111.118 179.879 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 50.01 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 70.41 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.34 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.02 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.15 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.31 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.41 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.3 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.51 ' O ' HG23 ' A' ' 19' ' ' VAL . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 72.14 110.905 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.03 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 16' ' ' LYS . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 41.11 111.139 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.42 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 42.34 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.432 HG22 ' HD3' ' A' ' 5' ' ' LYS . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.44 111.178 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.13 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 60.34 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' HG22 ' A' ' 2' ' ' THR . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.24 110.866 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.434 HD12 HG23 ' A' ' 7' ' ' VAL . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 33.15 110.909 179.909 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.434 HG23 HD12 ' A' ' 6' ' ' LEU . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.55 111.092 179.865 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 16' ' ' LYS . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 72.21 111.127 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.52 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 43.22 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 73.44 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 63.12 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.31 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.468 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.32 111.094 -179.96 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 53.14 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.489 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.55 110.854 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.42 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 72.45 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 63.1 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.969 179.905 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 61.310000000000002 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.319999999999993 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 62.039999999999999 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.430000000000007 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.109999999999999 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.495 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.349999999999994 110.913 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 72.239999999999995 111.162 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.489 HG13 ' HB ' ' A' ' 14' ' ' VAL . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 55.329999999999998 111.148 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 65.140000000000001 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.100000000000001 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.239999999999995 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.129999999999995 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.530000000000001 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.489 ' HB ' HG13 ' A' ' 8' ' ' VAL . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 55.119999999999997 111.125 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 72.549999999999997 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.449 ' HB2' HG21 ' A' ' 8' ' ' VAL . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.409999999999997 110.899 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.130000000000003 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.010000000000005 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.030000000000001 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.420000000000002 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.409999999999997 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 72.049999999999997 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.150000000000006 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 71.450000000000003 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.109999999999999 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.439999999999998 110.943 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.150000000000006 111.132 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.723 HG11 ' H ' ' A' ' 17' ' ' SER . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.409999999999997 111.177 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.349999999999994 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.310000000000002 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 63.210000000000001 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.329999999999998 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.406 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.530000000000001 111.123 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.210000000000001 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 74.519999999999996 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.723 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.430000000000007 110.825 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.340000000000003 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 71.219999999999999 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.130000000000003 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 72.430000000000007 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 53.439999999999998 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.040000000000006 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 64.530000000000001 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 73.120000000000005 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.200000000000003 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.618 HG13 ' HB ' ' A' ' 14' ' ' VAL . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 63.219999999999999 111.1 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.439999999999998 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 41.020000000000003 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 33.399999999999999 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.040000000000006 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.420000000000002 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.618 ' HB ' HG13 ' A' ' 8' ' ' VAL . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 51.32 111.199 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 72.200000000000003 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.129999999999995 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.61 ' H ' HG11 ' A' ' 8' ' ' VAL . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.129999999999995 110.812 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.340000000000003 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.239999999999995 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 74.140000000000001 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.209999999999994 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.530000000000001 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.219999999999999 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 73.230000000000004 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.492 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.140000000000001 110.939 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 6' ' ' LEU . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.239999999999995 111.128 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.736 HG11 ' H ' ' A' ' 17' ' ' SER . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 65.239999999999995 111.14 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 55.43 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 54.130000000000003 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 53.130000000000003 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.150000000000006 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.210000000000001 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 53.43 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.408 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.530000000000001 110.92 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.736 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 63.310000000000002 110.877 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 44.219999999999999 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 16' ' ' LYS . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.230000000000004 111.131 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 72.120000000000005 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.299999999999997 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.549999999999997 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.439999999999998 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.209999999999994 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 64.340000000000003 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.446 HD12 HG23 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 54.340000000000003 110.919 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 HD12 ' A' ' 6' ' ' LEU . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 62.009999999999998 111.107 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG13 ' HB ' ' A' ' 14' ' ' VAL . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 44.229999999999997 111.106 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 51.109999999999999 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.040000000000006 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 23.129999999999999 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 43.219999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 63.229999999999997 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.671 ' HB ' HG13 ' A' ' 8' ' ' VAL . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 44.130000000000003 111.149 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 64.420000000000002 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.319999999999993 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.602 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.310000000000002 110.857 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.420000000000002 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.409999999999997 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.239999999999995 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 71.409999999999997 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.423 HG22 ' HD3' ' A' ' 5' ' ' LYS . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.129999999999995 111.124 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.329999999999998 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.519999999999996 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.423 ' HD3' HG22 ' A' ' 2' ' ' THR . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 64.230000000000004 110.939 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.645 HD12 HG23 ' A' ' 7' ' ' VAL . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 70.010000000000005 110.888 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.645 HG23 HD12 ' A' ' 6' ' ' LEU . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 72.230000000000004 111.16 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 71.310000000000002 111.108 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 64.430000000000007 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.240000000000002 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.200000000000003 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.340000000000003 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 53.310000000000002 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.512 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.510000000000005 111.155 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.099999999999994 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.010000000000005 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 43.32 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.140000000000001 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 44.100000000000001 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.219999999999999 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.120000000000005 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 63.229999999999997 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.239999999999995 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 62.119999999999997 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 63.229999999999997 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 65.219999999999999 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.019999999999996 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.62 HG11 ' H ' ' A' ' 17' ' ' SER . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 52.140000000000001 111.126 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.239999999999995 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.310000000000002 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 65.519999999999996 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.120000000000005 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.099999999999994 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 54.25 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.329999999999998 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.030000000000001 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.62 ' H ' HG11 ' A' ' 8' ' ' VAL . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.129999999999995 110.859 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 62.539999999999999 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 64.150000000000006 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 61.299999999999997 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.310000000000002 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.239999999999995 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.310000000000002 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.530000000000001 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 71.329999999999998 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.497 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.349999999999994 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.497 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 63.030000000000001 111.109 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.531 HG13 ' HB ' ' A' ' 14' ' ' VAL . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.319999999999993 111.113 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.430000000000007 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 62.5 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 61.530000000000001 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.120000000000005 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.119999999999997 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.531 ' HB ' HG13 ' A' ' 8' ' ' VAL . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 54.409999999999997 111.128 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.519999999999996 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.494 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.400000000000006 110.932 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.519999999999996 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.329999999999998 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 71.010000000000005 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.450000000000003 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.230000000000004 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.439999999999998 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 31.129999999999999 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.420000000000002 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 54.140000000000001 110.949 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.489 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 64.420000000000002 111.13 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.484 HG11 ' HB2' ' A' ' 16' ' ' LYS . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 53.109999999999999 111.163 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 72.129999999999995 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.439999999999998 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.120000000000005 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.340000000000003 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.519999999999996 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.049999999999997 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.450000000000003 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.484 ' HB2' HG11 ' A' ' 8' ' ' VAL . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.149999999999999 110.861 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.439999999999998 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.209999999999994 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 72.530000000000001 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 73.530000000000001 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.530000000000001 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.219999999999999 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.019999999999996 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.120000000000005 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.340000000000003 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.49 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.319999999999993 110.906 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.49 HG23 ' CD1' ' A' ' 6' ' ' LEU . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.329999999999998 111.115 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.678 HG13 ' HB ' ' A' ' 14' ' ' VAL . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 44.329999999999998 111.109 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.340000000000003 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 63.240000000000002 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.100000000000001 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.239999999999995 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.340000000000003 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.678 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.120000000000005 111.158 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.140000000000001 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.616 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 64.25 110.923 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.400000000000006 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 54.219999999999999 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.509999999999998 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 72.209999999999994 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 63.43 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 71.400000000000006 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.329999999999998 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.040000000000006 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.530000000000001 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.420000000000002 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 65.420000000000002 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.683 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 54.25 111.15 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 62.229999999999997 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 25.219999999999999 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 54.030000000000001 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.430000000000007 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 62.210000000000001 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.683 ' HB ' HG13 ' A' ' 8' ' ' VAL . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 71.120000000000005 111.139 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 44.5 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.576 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 72.340000000000003 110.907 -179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.310000000000002 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.019999999999996 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 65.209999999999994 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 74.319999999999993 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.319999999999993 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 64.25 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.349999999999994 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.230000000000004 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.420000000000002 110.87 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 61.219999999999999 111.129 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.556 HG13 ' HB ' ' A' ' 14' ' ' VAL . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 53.039999999999999 111.075 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.109999999999999 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.010000000000005 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.219999999999999 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 64.310000000000002 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.310000000000002 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.556 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.200000000000003 111.095 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.109999999999999 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.444 ' HB2' HG21 ' A' ' 8' ' ' VAL . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.140000000000001 110.913 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.219999999999999 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.409999999999997 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.340000000000003 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 64.140000000000001 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 70.030000000000001 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 54.140000000000001 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 63.420000000000002 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 74.239999999999995 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.409999999999997 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.430000000000007 110.894 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.319999999999993 111.12 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.541 HG11 ' HB2' ' A' ' 16' ' ' LYS . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 73.120000000000005 111.145 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.219999999999999 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.540000000000006 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 64.109999999999999 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 65.230000000000004 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.319999999999993 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.409999999999997 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 44.539999999999999 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 65.409999999999997 110.912 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 53.520000000000003 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 71.319999999999993 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 62.229999999999997 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.540000000000006 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 73.310000000000002 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.439999999999998 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 63.350000000000001 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.420000000000002 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.219999999999999 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.513 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 73.129999999999995 110.923 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.513 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 50.310000000000002 111.129 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.659 HG11 ' H ' ' A' ' 17' ' ' SER . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.340000000000003 111.158 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 64.219999999999999 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 61.530000000000001 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 71.540000000000006 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.010000000000005 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 34.520000000000003 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.519 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 61.310000000000002 111.126 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 71.310000000000002 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.659 ' H ' HG11 ' A' ' 8' ' ' VAL . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 51.140000000000001 110.83 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.239999999999995 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 72.319999999999993 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.329999999999998 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 64.5 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.430000000000007 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.040000000000006 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.299999999999997 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.019999999999996 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.527 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.430000000000007 110.956 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.527 HG23 ' CD1' ' A' ' 6' ' ' LEU . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 54.329999999999998 111.072 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.711 HG11 ' H ' ' A' ' 17' ' ' SER . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 70.099999999999994 111.109 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 71.209999999999994 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.430000000000007 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 22.239999999999998 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 34.009999999999998 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.240000000000002 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.472 ' HB ' HG13 ' A' ' 8' ' ' VAL . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.409999999999997 111.118 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.310000000000002 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 42.100000000000001 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.711 ' H ' HG11 ' A' ' 8' ' ' VAL . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 64.099999999999994 110.911 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 55.420000000000002 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.450000000000003 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 74.299999999999997 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.129999999999995 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 34.030000000000001 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 65.439999999999998 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 61.520000000000003 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.310000000000002 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.535 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 62.520000000000003 110.943 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.535 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 72.239999999999995 111.127 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG11 ' HB2' ' A' ' 16' ' ' LYS . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 53.409999999999997 111.117 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.510000000000005 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.120000000000005 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.130000000000003 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.140000000000001 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 43.549999999999997 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 40.539999999999999 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.519999999999996 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.651 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.209999999999994 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.140000000000001 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.019999999999996 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.129999999999995 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.420000000000002 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.239999999999995 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.349999999999994 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.430000000000007 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 65.219999999999999 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.010000000000005 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 73.129999999999995 110.967 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 72.239999999999995 111.101 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.319999999999993 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 74.230000000000004 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.140000000000001 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 63.229999999999997 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 62.130000000000003 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.510000000000005 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.540000000000006 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.340000000000003 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 61.340000000000003 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 71.329999999999998 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.140000000000001 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 71.430000000000007 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.450000000000003 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 62.539999999999999 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.439999999999998 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.109999999999999 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.109999999999999 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 70.439999999999998 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.514 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.100000000000001 110.92 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 72.439999999999998 111.114 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.716 HG11 ' H ' ' A' ' 17' ' ' SER . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.149999999999999 111.144 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 63.030000000000001 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 71.549999999999997 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 41.020000000000003 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.109999999999999 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.439999999999998 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.486 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 71.140000000000001 111.105 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.140000000000001 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 52.219999999999999 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.716 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 55.409999999999997 110.893 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.409999999999997 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 71.349999999999994 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 54.530000000000001 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 72.310000000000002 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.329999999999998 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 65.549999999999997 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 65.340000000000003 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 73.519999999999996 110.894 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' CD1' ' A' ' 6' ' ' LEU . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.530000000000001 111.114 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.734 HG11 ' H ' ' A' ' 17' ' ' SER . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 62.299999999999997 111.107 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 72.519999999999996 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.340000000000003 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.32 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 64.140000000000001 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.109999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.049999999999997 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 34.109999999999999 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.447 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 64.25 110.9 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.734 ' H ' HG11 ' A' ' 8' ' ' VAL . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.420000000000002 110.852 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 73.519999999999996 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 16' ' ' LYS . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 61.25 111.139 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 74.439999999999998 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 63.509999999999998 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.430000000000007 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 64.329999999999998 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.150000000000006 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 74.420000000000002 110.873 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.349999999999994 111.131 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.694 HG11 ' HB2' ' A' ' 16' ' ' LYS . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 60.020000000000003 111.136 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.109999999999999 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 70.340000000000003 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.129999999999995 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 44.329999999999998 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.240000000000002 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 41.219999999999999 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.694 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.030000000000001 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 71.400000000000006 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.150000000000006 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.430000000000007 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.109999999999999 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 72.140000000000001 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.340000000000003 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.230000000000004 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.040000000000006 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 73.310000000000002 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.487 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.120000000000005 110.928 179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.487 HG23 ' CD1' ' A' ' 6' ' ' LEU . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 63.020000000000003 111.138 179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.542 HG11 ' HB2' ' A' ' 16' ' ' LYS . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.329999999999998 111.117 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 54.32 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 63.240000000000002 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.350000000000001 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.319999999999993 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.099999999999994 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 71.420000000000002 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.530000000000001 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.542 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.319999999999993 110.904 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.329999999999998 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.340000000000003 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 62.539999999999999 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.420000000000002 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.329999999999998 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 64.140000000000001 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.409999999999997 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.310000000000002 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 71.540000000000006 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.536 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 71.140000000000001 110.901 179.896 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.409999999999997 111.134 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.631 HG11 ' HB2' ' A' ' 17' ' ' SER . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.019999999999996 111.107 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 71.439999999999998 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 61.310000000000002 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.299999999999997 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.230000000000004 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.349999999999994 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 55.009999999999998 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.526 ' O ' HG23 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 71.140000000000001 110.893 -179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.631 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 40.119999999999997 110.861 -179.906 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 73.120000000000005 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 16' ' ' LYS . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.399999999999999 111.122 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.530000000000001 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 71.150000000000006 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 65.209999999999994 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.310000000000002 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 63.119999999999997 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 74.319999999999993 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 55.100000000000001 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.049999999999997 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' A' ' 17' ' ' SER . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.319999999999993 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 54.229999999999997 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.209999999999994 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.109999999999999 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.420000000000002 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.239999999999995 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.420000000000002 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.586 ' O ' HG23 ' A' ' 19' ' ' VAL . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 71.200000000000003 110.882 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.542 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.310000000000002 110.857 -179.917 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 64.439999999999998 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 16' ' ' LYS . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 62.43 111.122 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 60.119999999999997 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 61.119999999999997 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 61.299999999999997 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.409999999999997 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.319999999999993 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.409999999999997 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.51 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 52.32 110.87 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.51 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 73.510000000000005 111.118 179.879 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 50.009999999999998 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 70.409999999999997 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.340000000000003 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.019999999999996 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.150000000000006 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.310000000000002 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.409999999999997 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.299999999999997 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.51 ' O ' HG23 ' A' ' 19' ' ' VAL . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 72.140000000000001 110.905 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.030000000000001 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.510000000000005 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 16' ' ' LYS . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 41.109999999999999 111.139 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.420000000000002 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 42.340000000000003 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.432 HG22 ' HD3' ' A' ' 5' ' ' LYS . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.439999999999998 111.178 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.129999999999995 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 60.340000000000003 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' HG22 ' A' ' 2' ' ' THR . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.239999999999995 110.866 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.434 HD12 HG23 ' A' ' 7' ' ' VAL . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 33.149999999999999 110.909 179.909 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.434 HG23 HD12 ' A' ' 6' ' ' LEU . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.549999999999997 111.092 179.865 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 16' ' ' LYS . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 72.209999999999994 111.127 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.519999999999996 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 43.219999999999999 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 73.439999999999998 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 63.119999999999997 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.310000000000002 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.468 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.319999999999993 111.094 -179.96 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 53.140000000000001 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.489 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.549999999999997 110.854 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.420000000000002 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 72.450000000000003 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 63.100000000000001 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 63.509999999999998 110.969 179.905 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.7 ttm . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.87 0.367 . . . . 61.310000000000002 110.919 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -117.8 -27.06 6.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 75.319999999999993 111.145 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.1 tt0 -155.62 -65.83 0.12 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 62.039999999999999 110.867 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.94 -22.43 11.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 74.430000000000007 110.935 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.5 mtpp -61.75 -17.83 57.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 73.109999999999999 110.885 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.495 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -80.86 -16.31 54.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.232 -0.44 . . . . 74.349999999999994 110.913 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.495 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -113.07 -56.56 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.484 . . . . 72.239999999999995 111.162 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.489 HG13 ' HB ' ' A' ' 14' ' ' VAL . 89.0 t -63.08 -55.56 22.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 55.329999999999998 111.148 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.45 -25.23 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 65.140000000000001 111.133 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.87 -19.35 69.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.753 . . . . 52.100000000000001 112.493 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.66 -32.87 13.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.782 0.325 . . . . 74.239999999999995 111.115 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.31 -26.03 0.16 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 72.129999999999995 112.481 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.26 78.85 0.92 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.755 -0.736 . . . . 74.530000000000001 112.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.489 ' HB ' HG13 ' A' ' 8' ' ' VAL . 66.3 t -70.15 -37.63 72.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 55.119999999999997 111.125 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.4 22.87 5.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.762 -0.733 . . . . 72.549999999999997 112.501 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.449 ' HB2' HG21 ' A' ' 8' ' ' VAL . 30.6 mmmt -86.38 -48.26 8.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.815 0.341 . . . . 73.409999999999997 110.899 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -52.09 -30.11 24.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 62.130000000000003 110.865 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -51.96 -30.18 23.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.106 -0.497 . . . . 74.010000000000005 110.858 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.5 t -72.27 -37.08 57.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 73.030000000000001 111.109 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 74.420000000000002 110.931 179.969 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.6 ttp . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.901 0.381 . . . . 75.409999999999997 110.898 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.08 -28.08 5.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.451 . . . . 72.049999999999997 111.106 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -154.42 -65.56 0.14 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.248 -0.433 . . . . 75.150000000000006 110.901 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -111.1 -22.4 11.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 71.450000000000003 110.892 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.2 mtpm? -62.12 -17.43 57.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.137 -0.483 . . . . 73.109999999999999 110.852 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -81.47 -15.57 54.6 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.266 -0.425 . . . . 74.439999999999998 110.943 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.5 t -113.86 -56.51 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 73.150000000000006 111.132 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.723 HG11 ' H ' ' A' ' 17' ' ' SER . 66.3 t -64.33 -57.03 13.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 74.409999999999997 111.177 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -81.41 -25.47 10.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 72.349999999999994 111.106 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.45 -18.86 66.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.766 -0.73 . . . . 70.310000000000002 112.489 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -95.62 -46.43 6.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.861 0.362 . . . . 63.210000000000001 111.156 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.84 37.88 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.696 -0.764 . . . . 51.5 112.474 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 58.17 71.44 0.75 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.753 -0.737 . . . . 72.329999999999998 112.427 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.406 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.7 t -59.81 -33.93 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.855 0.36 . . . . 74.530000000000001 111.123 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.51 22.92 5.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.797 -0.716 . . . . 61.210000000000001 112.489 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.4 mmtt -103.72 -46.03 4.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.791 0.329 . . . . 74.519999999999996 110.888 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.723 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.1 t -53.64 -28.36 32.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.269 -0.423 . . . . 75.430000000000007 110.825 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -55.53 -27.39 48.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 74.340000000000003 110.852 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.3 t -65.11 -47.25 88.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 71.219999999999999 111.173 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 60.5 m95 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.132 -0.486 . . . . 63.130000000000003 110.897 179.962 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.877 0.37 . . . . 72.430000000000007 110.864 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.73 -29.73 5.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 53.439999999999998 111.097 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -152.89 -65.67 0.16 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 110.892 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.7 -22.55 11.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.040000000000006 110.928 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 9.8 mttm -61.63 -17.93 57.36 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.123 -0.49 . . . . 64.530000000000001 110.898 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.1 pp -82.26 -14.54 55.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.225 -0.443 . . . . 73.120000000000005 110.954 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.3 -56.36 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 74.200000000000003 111.158 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.618 HG13 ' HB ' ' A' ' 14' ' ' VAL . 69.0 t -65.22 -57.64 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 63.219999999999999 111.1 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.9 t -80.65 -25.9 11.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 65.439999999999998 111.162 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.18 -19.52 66.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.739 -0.743 . . . . 41.020000000000003 112.465 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.92 -53.48 3.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 33.399999999999999 111.12 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.77 34.6 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.748 -0.739 . . . . 73.040000000000006 112.511 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 59.36 72.31 0.63 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 55.420000000000002 112.485 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.618 ' HB ' HG13 ' A' ' 8' ' ' VAL . 37.7 t -60.59 -34.64 59.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.907 0.384 . . . . 51.32 111.199 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.5 19.17 7.6 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.752 -0.737 . . . . 72.200000000000003 112.519 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.0 mmmt -98.93 -53.71 3.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.826 0.346 . . . . 73.129999999999995 110.906 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.61 ' H ' HG11 ' A' ' 8' ' ' VAL . 5.9 t -52.05 -30.17 24.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 74.129999999999995 110.812 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -51.98 -30.62 25.75 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 75.340000000000003 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -66.61 -47.32 83.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 72.239999999999995 111.157 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 91.5 m95 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.111 -0.495 . . . . 74.140000000000001 110.928 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ttm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.806 0.336 . . . . 73.0 110.862 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.76 -29.67 5.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 73.209999999999994 111.127 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -152.73 -65.5 0.16 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 72.530000000000001 110.88 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.8 -22.5 11.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 74.219999999999999 110.947 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpt -62.2 -17.35 57.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.085 -0.507 . . . . 73.230000000000004 110.892 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.492 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.6 pp -82.37 -14.36 55.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 74.140000000000001 110.939 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.492 HG23 ' CD1' ' A' ' 6' ' ' LEU . 97.2 t -114.32 -56.35 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 74.239999999999995 111.128 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.736 HG11 ' H ' ' A' ' 17' ' ' SER . 60.8 t -65.84 -58.29 7.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 65.239999999999995 111.14 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -78.8 -26.23 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 55.43 111.079 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.11 -19.51 61.62 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 54.130000000000003 112.506 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -83.4 -42.92 16.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.811 0.339 . . . . 53.130000000000003 111.119 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.25 -31.34 0.19 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.789 -0.72 . . . . 70.150000000000006 112.498 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.56 89.21 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.738 -0.744 . . . . 53.210000000000001 112.47 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.8 t -85.95 -39.39 13.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 53.43 111.135 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.22 19.34 7.64 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.699 -0.762 . . . . 60.43 112.511 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.408 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.6 mmpt? -99.59 -61.06 1.42 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 74.530000000000001 110.92 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.736 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.2 t -52.05 -30.04 23.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 63.310000000000002 110.877 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 17.7 m80 -51.96 -30.14 23.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 44.219999999999999 110.83 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 16' ' ' LYS . 79.0 t -57.73 -47.37 85.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.449 . . . . 71.230000000000004 111.131 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 46.3 m95 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.165 -0.47 . . . . 72.120000000000005 110.924 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttp . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.789 0.328 . . . . 74.299999999999997 110.883 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.4 t -118.62 -30.46 5.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 74.549999999999997 111.133 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 -153.16 -67.01 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.274 -0.421 . . . . 72.439999999999998 110.893 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.92 -22.14 12.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.138 -0.483 . . . . 75.209999999999994 110.934 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.3 mtpp -60.88 -18.51 56.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.145 -0.479 . . . . 64.340000000000003 110.87 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.446 HD12 HG23 ' A' ' 7' ' ' VAL . 0.9 OUTLIER -80.01 -16.24 55.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.229 -0.441 . . . . 54.340000000000003 110.919 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.446 HG23 HD12 ' A' ' 6' ' ' LEU . 95.7 t -114.02 -58.99 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 62.009999999999998 111.107 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG13 ' HB ' ' A' ' 14' ' ' VAL . 49.1 t -59.88 -52.3 62.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 44.229999999999997 111.106 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 19.8 t -89.14 -24.82 5.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 51.109999999999999 111.119 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.47 -19.31 74.41 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.741 -0.743 . . . . 72.040000000000006 112.466 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -93.85 -53.2 4.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.812 0.339 . . . . 23.129999999999999 111.106 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 178.05 33.06 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 43.219999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 55.97 69.58 1.23 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.734 -0.746 . . . . 63.229999999999997 112.5 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.671 ' HB ' HG13 ' A' ' 8' ' ' VAL . 45.9 t -56.22 -35.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.883 0.373 . . . . 44.130000000000003 111.149 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.81 17.91 10.6 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.774 -0.726 . . . . 64.420000000000002 112.524 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -95.22 -47.73 6.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.747 0.308 . . . . 73.319999999999993 110.907 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.602 ' H ' HG11 ' A' ' 8' ' ' VAL . 6.5 t -52.07 -29.96 23.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 75.310000000000002 110.857 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 23.8 m80 -52.49 -29.2 23.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 74.420000000000002 110.873 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -70.27 -43.95 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.409999999999997 111.134 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.0 m95 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 74.239999999999995 110.939 179.981 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ttt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.832 0.349 . . . . 71.409999999999997 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.423 HG22 ' HD3' ' A' ' 5' ' ' LYS . 14.2 t -118.34 -30.26 5.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.129999999999995 111.124 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -176.3 -65.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 75.329999999999998 110.903 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -110.47 -22.54 11.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.182 -0.463 . . . . 64.519999999999996 110.902 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.423 ' HD3' HG22 ' A' ' 2' ' ' THR . 2.1 mtpm? -60.47 -19.47 56.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.141 -0.481 . . . . 64.230000000000004 110.939 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.645 HD12 HG23 ' A' ' 7' ' ' VAL . 1.3 pp -79.1 -16.42 56.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 70.010000000000005 110.888 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.645 HG23 HD12 ' A' ' 6' ' ' LEU . 96.1 t -112.41 -56.59 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 72.230000000000004 111.16 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.512 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.9 t -61.8 -53.9 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 71.310000000000002 111.108 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -87.52 -25.42 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 64.430000000000007 111.132 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.48 -19.72 73.0 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.74 . . . . 52.240000000000002 112.459 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.21 -37.99 11.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.833 0.349 . . . . 74.200000000000003 111.11 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -178.77 -45.88 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.716 -0.754 . . . . 74.340000000000003 112.486 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 128.46 86.53 0.51 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.73 -0.748 . . . . 53.310000000000002 112.464 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.512 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -79.99 -39.88 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.888 0.375 . . . . 70.510000000000005 111.155 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.2 19.92 5.35 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.733 -0.746 . . . . 73.099999999999994 112.48 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 14.8 mmmm -78.63 -51.5 9.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 74.010000000000005 110.935 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.9 t -52.04 -31.47 30.16 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 43.32 110.9 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -53.96 -27.87 33.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.140000000000001 110.872 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.7 t -82.02 -56.83 5.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 44.100000000000001 111.132 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 56.7 m95 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 116.17 -0.468 . . . . 74.219999999999999 110.945 179.956 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.9 ttp . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 75.120000000000005 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -119.05 -30.02 5.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.261 -0.427 . . . . 63.229999999999997 111.129 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -152.57 -65.63 0.16 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 74.239999999999995 110.896 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.6 -22.48 11.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.125 -0.489 . . . . 62.119999999999997 110.926 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -61.56 -17.9 56.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.104 -0.498 . . . . 63.229999999999997 110.931 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.6 pp -83.23 -13.08 56.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 65.219999999999999 110.903 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 32.9 t -114.14 -56.13 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 74.019999999999996 111.111 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.62 HG11 ' H ' ' A' ' 17' ' ' SER . 92.2 t -65.39 -57.66 10.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 52.140000000000001 111.126 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -80.03 -30.29 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 73.239999999999995 111.168 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.96 -21.32 58.81 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.767 -0.73 . . . . 64.310000000000002 112.482 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.79 -31.45 18.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 65.519999999999996 111.084 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.35 -22.73 0.29 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 65.120000000000005 112.479 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 111.13 75.11 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.703 -0.76 . . . . 73.099999999999994 112.491 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -67.94 -38.87 80.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.871 0.367 . . . . 54.25 111.114 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.25 22.18 5.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.72 -0.752 . . . . 63.329999999999998 112.458 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -94.56 -49.75 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.726 0.298 . . . . 74.030000000000001 110.874 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.62 ' H ' HG11 ' A' ' 8' ' ' VAL . 2.0 t -51.99 -30.2 24.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 73.129999999999995 110.859 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.9 m80 -52.25 -30.02 25.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 62.539999999999999 110.813 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 72.7 t -62.46 -41.2 90.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 64.150000000000006 111.099 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 87.9 m95 . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 61.299999999999997 110.94 179.968 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttp . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.877 0.37 . . . . 74.310000000000002 110.891 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.79 -29.82 5.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 73.239999999999995 111.148 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -152.72 -65.59 0.16 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.310000000000002 110.892 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.65 -22.32 11.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 75.530000000000001 110.931 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.4 mtpt -62.28 -17.12 57.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.11 -0.495 . . . . 71.329999999999998 110.894 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.497 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -83.23 -13.46 55.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.25 -0.432 . . . . 75.349999999999994 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.497 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.6 t -115.3 -57.24 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 63.030000000000001 111.109 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.531 HG13 ' HB ' ' A' ' 14' ' ' VAL . 57.3 t -67.41 -60.25 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 64.319999999999993 111.113 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.5 t -74.06 -25.62 20.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.159 -0.473 . . . . 72.430000000000007 111.18 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.99 -20.6 66.97 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.75 -0.738 . . . . 62.5 112.48 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -82.09 -42.67 18.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 61.530000000000001 111.091 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.43 -22.84 0.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.711 -0.756 . . . . 74.120000000000005 112.479 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.74 91.61 0.53 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 62.119999999999997 112.515 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.531 ' HB ' HG13 ' A' ' 8' ' ' VAL . 52.8 t -89.95 -36.51 8.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.894 0.378 . . . . 54.409999999999997 111.128 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.74 19.46 7.35 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 74.519999999999996 112.493 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.494 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -98.09 -60.09 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 75.400000000000006 110.932 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.1 t -52.05 -30.12 24.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 73.519999999999996 110.891 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -52.45 -29.9 27.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 70.329999999999998 110.865 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 55.9 t -69.37 -50.07 54.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 71.010000000000005 111.111 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 61.7 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.238 -0.437 . . . . 74.450000000000003 110.917 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.843 0.354 . . . . 72.230000000000004 110.848 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -29.85 5.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 71.439999999999998 111.13 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -152.57 -65.51 0.16 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 31.129999999999999 110.869 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.83 -22.25 11.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -62.06 -17.43 57.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 73.420000000000002 110.907 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.9 pp -83.19 -13.13 56.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.442 . . . . 54.140000000000001 110.949 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.489 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.0 t -114.91 -56.18 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 64.420000000000002 111.13 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.484 HG11 ' HB2' ' A' ' 16' ' ' LYS . 50.5 t -65.61 -58.25 7.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.14 -0.482 . . . . 53.109999999999999 111.163 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.3 t -78.45 -30.66 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 72.129999999999995 111.183 179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.12 -19.63 57.2 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.688 -0.767 . . . . 65.439999999999998 112.516 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.51 -44.77 13.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.834 0.35 . . . . 75.120000000000005 111.116 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.3 -28.92 0.16 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 64.340000000000003 112.525 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.35 91.46 0.64 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 71.519999999999996 112.462 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.38 -36.35 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.899 0.38 . . . . 73.049999999999997 111.127 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.97 19.92 7.03 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.764 -0.732 . . . . 64.450000000000003 112.471 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.484 ' HB2' HG11 ' A' ' 8' ' ' VAL . 7.1 mmpt? -95.76 -57.98 2.23 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.784 0.326 . . . . 63.149999999999999 110.861 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.4 t -52.06 -30.32 25.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 73.439999999999998 110.843 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -53.81 -28.51 35.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.107 -0.497 . . . . 71.209999999999994 110.888 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 53.3 t -69.15 -50.35 53.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.455 . . . . 72.530000000000001 111.186 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 34.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 73.530000000000001 110.937 179.935 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.8 ttm . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.875 0.369 . . . . 73.530000000000001 110.932 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.2 t -118.74 -29.38 5.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 73.219999999999999 111.168 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -153.12 -65.73 0.15 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 74.019999999999996 110.875 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.52 -22.23 11.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.156 -0.475 . . . . 74.120000000000005 110.932 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.7 mtpp -62.62 -16.84 58.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.340000000000003 110.9 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.49 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -83.16 -13.95 54.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.468 . . . . 71.319999999999993 110.906 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.49 HG23 ' CD1' ' A' ' 6' ' ' LEU . 77.7 t -115.36 -57.62 3.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.45 . . . . 72.329999999999998 111.115 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.678 HG13 ' HB ' ' A' ' 14' ' ' VAL . 74.2 t -67.3 -60.24 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 44.329999999999998 111.109 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -73.67 -25.18 20.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 53.340000000000003 111.1 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.17 -18.7 58.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.737 -0.744 . . . . 63.240000000000002 112.445 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.53 -35.79 14.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 63.100000000000001 111.097 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 154.8 -21.99 0.61 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.744 . . . . 72.239999999999995 112.506 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.04 93.5 0.73 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.699 -0.762 . . . . 73.340000000000003 112.452 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.678 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -87.58 -30.01 5.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.897 0.38 . . . . 74.120000000000005 111.158 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 115.02 21.9 5.14 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.724 -0.75 . . . . 63.140000000000001 112.516 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.616 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -100.5 -64.26 1.06 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.764 0.316 . . . . 64.25 110.923 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -52.07 -30.13 24.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 75.400000000000006 110.826 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -53.33 -28.59 29.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 54.219999999999999 110.884 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.2 t -78.98 -54.67 11.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 62.509999999999998 111.136 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 48.2 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.197 -0.456 . . . . 72.209999999999994 110.923 179.966 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.9 ttt . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.852 0.358 . . . . 63.43 110.922 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.0 t -119.17 -30.46 4.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 71.400000000000006 111.155 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -152.13 -65.9 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 74.329999999999998 110.896 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.19 -22.07 11.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.474 . . . . 75.040000000000006 110.926 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.7 mtpp -61.91 -17.53 57.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.084 -0.507 . . . . 73.530000000000001 110.896 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.8 pp -84.63 -10.94 56.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 64.420000000000002 110.936 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.08 -56.1 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 65.420000000000002 111.161 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.683 HG13 ' HB ' ' A' ' 14' ' ' VAL . 94.0 t -67.87 -60.6 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 54.25 111.15 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.9 t -73.54 -32.56 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.147 -0.479 . . . . 62.229999999999997 111.147 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -55.59 -24.0 37.86 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.689 -0.767 . . . . 25.219999999999999 112.547 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.31 -39.89 17.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 54.030000000000001 111.117 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 160.39 -24.37 0.27 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.763 -0.732 . . . . 72.430000000000007 112.465 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.12 94.66 0.77 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.707 -0.758 . . . . 62.210000000000001 112.496 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.683 ' HB ' HG13 ' A' ' 8' ' ' VAL . 40.0 t -90.03 -31.54 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 71.120000000000005 111.139 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.25 19.78 6.16 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.749 -0.738 . . . . 44.5 112.48 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.576 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -95.66 -63.15 1.19 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 72.340000000000003 110.907 -179.988 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 t -52.0 -30.16 24.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 63.310000000000002 110.839 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -53.9 -27.85 32.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.019999999999996 110.864 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.1 t -78.8 -53.2 14.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.459 . . . . 65.209999999999994 111.155 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 29.4 m95 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.149 -0.478 . . . . 74.319999999999993 110.942 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.798 0.333 . . . . 74.319999999999993 110.827 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.66 -28.27 6.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 64.25 111.146 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.7 tp10 -153.99 -67.09 0.14 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 75.349999999999994 110.873 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.16 -22.15 12.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.5 110.949 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -65.71 -14.44 61.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.084 -0.507 . . . . 74.230000000000004 110.916 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -84.3 -19.8 33.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 74.420000000000002 110.87 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.1 t -110.2 -57.17 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 61.219999999999999 111.129 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.556 HG13 ' HB ' ' A' ' 14' ' ' VAL . 58.0 t -61.98 -53.96 40.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 53.039999999999999 111.075 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.13 -26.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 74.109999999999999 111.186 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -68.17 -19.59 72.28 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.727 -0.749 . . . . 72.010000000000005 112.515 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.85 -38.3 13.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 72.219999999999999 111.133 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.17 -37.73 0.16 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.759 -0.734 . . . . 64.310000000000002 112.504 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.6 89.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 70.310000000000002 112.464 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.556 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.9 t -86.29 -37.83 11.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.841 0.353 . . . . 75.200000000000003 111.095 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.6 24.48 5.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.698 -0.763 . . . . 63.109999999999999 112.479 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.444 ' HB2' HG21 ' A' ' 8' ' ' VAL . 27.6 mmmt -90.95 -50.3 5.95 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.766 0.317 . . . . 75.140000000000001 110.913 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.5 t -52.17 -30.41 26.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 71.219999999999999 110.83 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.48 -28.56 45.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.118 -0.492 . . . . 71.409999999999997 110.825 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 70.7 t -69.5 -53.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.340000000000003 111.121 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.9 m95 . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.473 . . . . 64.140000000000001 110.922 179.998 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 tpt . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.841 0.353 . . . . 70.030000000000001 110.837 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.6 t -114.41 -27.54 7.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 54.140000000000001 111.156 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -172.03 -65.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 63.420000000000002 110.879 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.72 -22.21 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 74.239999999999995 110.912 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.1 mttm -60.38 -19.64 56.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 73.409999999999997 110.92 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.4 pp -79.36 -16.53 56.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 64.430000000000007 110.894 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.1 t -111.55 -56.64 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 72.319999999999993 111.12 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.541 HG11 ' HB2' ' A' ' 16' ' ' LYS . 36.8 t -61.17 -53.04 54.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 73.120000000000005 111.145 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -89.43 -26.73 5.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 74.219999999999999 111.141 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.61 -19.48 69.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.749 -0.739 . . . . 74.540000000000006 112.522 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.22 -42.77 11.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.862 0.363 . . . . 64.109999999999999 111.114 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.73 -42.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.74 . . . . 65.230000000000004 112.492 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.95 86.24 0.38 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.76 -0.734 . . . . 75.319999999999993 112.495 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.5 t -84.53 -40.52 15.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.819 0.342 . . . . 72.409999999999997 111.129 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.38 20.56 6.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.754 -0.736 . . . . 44.539999999999999 112.448 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -83.49 -51.78 7.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.806 0.336 . . . . 65.409999999999997 110.912 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.1 t -52.12 -30.14 25.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 53.520000000000003 110.831 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -52.05 -30.11 24.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.156 -0.475 . . . . 71.319999999999993 110.883 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 54.7 t -72.17 -48.11 50.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 62.229999999999997 111.123 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 51.3 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.167 -0.47 . . . . 74.540000000000006 110.907 -179.993 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.7 tmm? . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.892 0.377 . . . . 73.310000000000002 110.917 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.0 t -105.89 -29.6 9.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.209 -0.45 . . . . 73.439999999999998 111.156 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -172.88 -66.08 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.236 -0.438 . . . . 63.350000000000001 110.915 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.99 -22.11 11.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.101 -0.5 . . . . 73.420000000000002 110.976 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 15.1 mttt -60.86 -18.42 56.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.075 -0.511 . . . . 75.219999999999999 110.883 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.513 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -80.41 -16.21 54.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 73.129999999999995 110.923 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.513 HG23 ' CD1' ' A' ' 6' ' ' LEU . 95.0 t -112.65 -56.36 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 50.310000000000002 111.129 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.659 HG11 ' H ' ' A' ' 17' ' ' SER . 62.9 t -62.5 -54.76 29.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.151 -0.477 . . . . 75.340000000000003 111.158 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.7 t -85.99 -26.36 6.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 64.219999999999999 111.171 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.06 -19.04 67.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 61.530000000000001 112.485 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.74 -25.11 19.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.343 . . . . 71.540000000000006 111.104 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.17 -19.32 0.94 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 74.010000000000005 112.5 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.32 85.53 1.49 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 34.520000000000003 112.477 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.519 ' HB ' HG13 ' A' ' 8' ' ' VAL . 23.0 t -73.35 -36.75 49.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.882 0.373 . . . . 61.310000000000002 111.126 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 113.61 19.65 6.47 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.747 -0.74 . . . . 71.310000000000002 112.491 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 10.8 mmtt -104.37 -45.77 4.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 110.877 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.659 ' H ' HG11 ' A' ' 8' ' ' VAL . 28.5 t -52.25 -29.84 24.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 51.140000000000001 110.83 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -57.62 -34.63 69.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 75.239999999999995 110.88 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 75.3 t -58.18 -57.82 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 72.319999999999993 111.102 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 41.9 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.329999999999998 110.929 179.969 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.3 ttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.825 0.345 . . . . 64.5 110.896 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -30.64 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 74.430000000000007 111.162 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -151.47 -66.68 0.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.228 -0.442 . . . . 75.040000000000006 110.885 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.79 12.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.11 -0.495 . . . . 73.299999999999997 110.933 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.0 mtpp -66.73 -13.62 61.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 73.019999999999996 110.897 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.527 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.34 -19.93 30.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 73.430000000000007 110.956 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.527 HG23 ' CD1' ' A' ' 6' ' ' LEU . 89.6 t -110.75 -57.87 3.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 54.329999999999998 111.072 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.711 HG11 ' H ' ' A' ' 17' ' ' SER . 85.0 t -63.31 -55.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 70.099999999999994 111.109 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.91 -25.77 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 71.209999999999994 111.142 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.37 -19.68 76.24 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.747 -0.739 . . . . 74.430000000000007 112.481 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.65 -25.83 22.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.808 0.337 . . . . 22.239999999999998 111.09 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 150.52 -19.26 1.02 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 34.009999999999998 112.498 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.82 82.78 1.19 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.776 -0.726 . . . . 63.240000000000002 112.507 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.472 ' HB ' HG13 ' A' ' 8' ' ' VAL . 22.1 t -72.25 -37.19 58.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.36 . . . . 74.409999999999997 111.118 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.84 23.11 6.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.765 -0.731 . . . . 74.310000000000002 112.488 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -106.7 -46.72 3.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 42.100000000000001 110.903 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.711 ' H ' HG11 ' A' ' 8' ' ' VAL . 4.9 t -54.31 -30.14 50.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 64.099999999999994 110.911 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 9.1 m80 -52.04 -32.87 36.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.131 -0.486 . . . . 55.420000000000002 110.844 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.2 t -55.16 -49.63 70.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 74.450000000000003 111.158 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 92.7 m95 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.14 -0.482 . . . . 74.299999999999997 110.939 179.962 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.7 ttp . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.888 0.375 . . . . 74.129999999999995 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 t -117.89 -30.89 5.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.229 -0.441 . . . . 34.030000000000001 111.129 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -151.13 -66.66 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.201 -0.454 . . . . 65.439999999999998 110.877 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.26 -21.81 12.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.13 -0.486 . . . . 61.520000000000003 110.942 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 11.7 mttm -66.69 -13.72 61.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 75.310000000000002 110.895 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.535 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.9 pp -85.31 -19.07 32.07 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 62.520000000000003 110.943 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.535 HG23 ' CD1' ' A' ' 6' ' ' LEU . 93.2 t -111.47 -57.82 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 72.239999999999995 111.127 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG11 ' HB2' ' A' ' 16' ' ' LYS . 63.9 t -64.05 -56.61 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 53.409999999999997 111.117 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -82.22 -25.36 9.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 74.510000000000005 111.073 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.19 -19.48 70.29 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.761 -0.733 . . . . 64.120000000000005 112.491 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.79 -40.19 16.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 53.130000000000003 111.122 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.87 -38.73 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.784 -0.722 . . . . 70.140000000000001 112.511 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 130.19 90.38 0.57 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.731 -0.747 . . . . 43.549999999999997 112.436 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -86.35 -37.58 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.87 0.367 . . . . 40.539999999999999 111.193 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.95 25.09 4.94 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.703 -0.76 . . . . 71.519999999999996 112.503 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.651 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.6 mmmt -91.59 -48.48 6.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 73.209999999999994 110.908 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.5 t -52.16 -29.95 24.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 65.140000000000001 110.857 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -51.95 -30.06 23.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 74.019999999999996 110.886 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.42 -50.33 63.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 72.129999999999995 111.149 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 94.5 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.144 -0.48 . . . . 73.420000000000002 110.892 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.6 ttt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.863 0.363 . . . . 72.239999999999995 110.848 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.12 -30.7 5.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.45 . . . . 75.349999999999994 111.134 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -151.29 -66.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 72.430000000000007 110.921 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.23 -21.75 12.65 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 65.219999999999999 110.949 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.2 mttm -66.88 -13.53 61.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.496 . . . . 73.010000000000005 110.895 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' A' ' 7' ' ' VAL . 1.8 pp -85.54 -18.76 32.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 73.129999999999995 110.967 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.5 t -112.03 -57.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 72.239999999999995 111.101 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 85.6 t -64.67 -57.46 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.189 -0.459 . . . . 75.319999999999993 111.128 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.6 t -80.15 -25.55 11.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 74.230000000000004 111.182 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.16 -19.85 70.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.769 -0.729 . . . . 62.140000000000001 112.497 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.89 -45.44 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 63.229999999999997 111.112 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -175.97 -41.49 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.766 -0.731 . . . . 62.130000000000003 112.497 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.74 90.92 0.6 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 73.510000000000005 112.49 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.39 -36.84 11.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.871 0.367 . . . . 74.540000000000006 111.139 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.75 19.6 7.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.71 -0.757 . . . . 73.340000000000003 112.513 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmmt -76.78 -49.1 16.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.841 0.353 . . . . 61.340000000000003 110.9 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.6 t -52.27 -30.6 28.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.228 -0.442 . . . . 71.329999999999998 110.897 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.8 m80 -54.01 -29.14 42.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.087 -0.506 . . . . 73.140000000000001 110.892 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 76.8 t -73.07 -49.59 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.465 . . . . 71.430000000000007 111.09 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 31.8 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 70.450000000000003 110.907 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.1 ttt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.852 0.358 . . . . 62.539999999999999 110.893 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.16 -29.41 5.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 75.439999999999998 111.19 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -152.83 -66.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 75.109999999999999 110.896 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.24 -22.08 12.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 74.109999999999999 110.91 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 8.4 mttm -66.01 -14.19 61.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 70.439999999999998 110.9 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.514 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.1 pp -85.14 -17.29 37.68 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.443 . . . . 62.100000000000001 110.92 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.73 -57.25 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.185 -0.461 . . . . 72.439999999999998 111.114 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.716 HG11 ' H ' ' A' ' 17' ' ' SER . 71.7 t -65.27 -57.79 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 61.149999999999999 111.144 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.66 -26.44 12.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.471 . . . . 63.030000000000001 111.1 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.95 -19.38 65.58 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.784 -0.722 . . . . 71.549999999999997 112.496 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.72 -53.62 4.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.778 0.323 . . . . 41.020000000000003 111.094 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.98 36.19 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.723 -0.751 . . . . 72.109999999999999 112.471 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.96 72.19 0.69 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 72.439999999999998 112.535 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.486 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.8 t -59.41 -35.38 58.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.378 . . . . 71.140000000000001 111.105 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.09 20.36 6.77 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.726 -0.75 . . . . 61.140000000000001 112.497 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -107.46 -45.9 3.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.76 0.314 . . . . 52.219999999999999 110.893 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.716 ' H ' HG11 ' A' ' 8' ' ' VAL . 1.5 t -54.87 -28.42 50.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 55.409999999999997 110.893 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -53.91 -29.04 40.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.158 -0.474 . . . . 75.409999999999997 110.841 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.1 t -61.3 -45.01 99.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 71.349999999999994 111.113 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 89.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 54.530000000000001 110.93 -179.995 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.0 ttm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.865 0.364 . . . . 72.310000000000002 110.859 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.22 -28.31 5.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.219 -0.446 . . . . 73.25 111.12 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.4 tp10 -154.07 -67.32 0.14 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 72.329999999999998 110.904 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -107.92 -22.16 12.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.135 -0.484 . . . . 65.549999999999997 110.971 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.6 mttt -64.99 -15.03 61.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.076 -0.511 . . . . 65.340000000000003 110.905 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.424 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.1 -16.44 40.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 73.519999999999996 110.894 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' CD1' ' A' ' 6' ' ' LEU . 47.3 t -112.17 -56.78 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.189 -0.459 . . . . 75.530000000000001 111.114 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.734 HG11 ' H ' ' A' ' 17' ' ' SER . 88.5 t -64.98 -57.23 12.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 62.299999999999997 111.107 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.38 -27.83 10.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 72.519999999999996 111.137 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.47 -19.26 57.58 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 62.340000000000003 112.513 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.58 -45.11 12.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.845 0.355 . . . . 63.32 111.122 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 172.81 -36.96 0.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 64.140000000000001 112.495 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.74 86.67 0.28 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 63.109999999999999 112.501 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 t -82.02 -41.19 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.374 . . . . 74.049999999999997 111.122 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.71 19.69 7.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.782 -0.723 . . . . 34.109999999999999 112.486 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.447 ' O ' HG23 ' A' ' 19' ' ' VAL . 7.2 mmpt? -99.54 -59.64 1.68 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.807 0.337 . . . . 64.25 110.9 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.734 ' H ' HG11 ' A' ' 8' ' ' VAL . 0.8 OUTLIER -52.29 -30.13 26.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 71.420000000000002 110.852 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -51.99 -30.32 24.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 73.519999999999996 110.906 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 16' ' ' LYS . 72.9 t -56.39 -46.65 81.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 61.25 111.139 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 28.5 m95 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.141 -0.482 . . . . 74.439999999999998 110.925 179.975 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.1 ttt . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.86 0.362 . . . . 73.0 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.3 t -118.82 -30.81 4.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 63.509999999999998 111.129 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -151.11 -66.78 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 73.430000000000007 110.852 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.13 -21.96 12.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 64.329999999999998 110.923 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.5 mtpp -66.39 -13.8 61.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 74.150000000000006 110.925 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.517 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.2 pp -86.33 -17.18 35.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.182 -0.463 . . . . 74.420000000000002 110.873 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 6' ' ' LEU . 94.6 t -112.56 -57.88 3.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 71.349999999999994 111.131 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.694 HG11 ' HB2' ' A' ' 16' ' ' LYS . 60.9 t -66.2 -58.71 5.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 60.020000000000003 111.136 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.38 -26.52 15.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 75.109999999999999 111.137 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.07 -20.16 57.7 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.748 -0.739 . . . . 70.340000000000003 112.486 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -85.05 -42.16 15.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 72.129999999999995 111.056 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 170.18 -37.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 44.329999999999998 112.482 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.47 91.47 0.45 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.71 -0.757 . . . . 50.240000000000002 112.494 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 42.5 t -87.03 -31.55 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.843 0.354 . . . . 41.219999999999999 111.112 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.62 19.23 7.52 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.687 -0.768 . . . . 64.25 112.43 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.694 ' HB2' HG11 ' A' ' 8' ' ' VAL . 8.2 mmpt? -93.37 -59.21 2.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.752 0.311 . . . . 75.030000000000001 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 t -51.96 -30.24 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 71.400000000000006 110.864 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 2.1 m80 -51.96 -30.29 24.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.126 -0.488 . . . . 73.150000000000006 110.895 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.2 t -66.06 -49.02 79.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.168 -0.469 . . . . 71.430000000000007 111.151 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.147 -0.479 . . . . 74.109999999999999 110.907 179.975 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.2 tmm? . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.884 0.373 . . . . 72.140000000000001 110.874 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.1 t -103.04 -28.93 11.68 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 70.340000000000003 111.134 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -173.32 -66.6 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 72.230000000000004 110.888 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.72 -21.56 12.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.172 -0.467 . . . . 71.040000000000006 110.92 -179.869 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -59.98 -19.09 50.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.138 -0.483 . . . . 73.310000000000002 110.926 179.876 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.487 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.7 pp -81.16 -13.41 58.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 74.120000000000005 110.928 179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.487 HG23 ' CD1' ' A' ' 6' ' ' LEU . 87.9 t -114.64 -56.25 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 63.020000000000003 111.138 179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.542 HG11 ' HB2' ' A' ' 16' ' ' LYS . 43.7 t -65.95 -58.52 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 74.329999999999998 111.117 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.1 t -78.22 -26.01 14.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 54.32 111.138 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.32 -19.66 68.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.785 -0.721 . . . . 63.240000000000002 112.466 -179.965 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.84 -35.87 18.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.807 0.336 . . . . 52.350000000000001 111.084 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 161.14 -23.59 0.24 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.752 -0.737 . . . . 73.319999999999993 112.472 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 119.16 91.9 1.4 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 73.099999999999994 112.528 -179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.0 t -87.99 -35.76 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.88 0.372 . . . . 71.420000000000002 111.125 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.32 19.74 7.39 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 75.530000000000001 112.505 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.542 ' HB2' HG11 ' A' ' 8' ' ' VAL . 14.8 mmmm -88.11 -52.09 5.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 75.319999999999993 110.904 179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -52.07 -30.4 25.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 74.329999999999998 110.841 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -53.63 -28.97 35.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 72.340000000000003 110.858 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.5 t -74.95 -50.79 23.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 62.539999999999999 111.139 -179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 88.0 m95 . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.473 . . . . 73.420000000000002 110.953 179.921 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.0 ttm . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.852 0.358 . . . . 71.329999999999998 110.89 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.5 t -118.03 -29.43 5.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.448 . . . . 64.140000000000001 111.155 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -152.75 -67.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 71.409999999999997 110.856 -179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -108.11 -21.92 12.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 73.310000000000002 110.906 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.3 mtpt -66.17 -14.04 61.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.484 . . . . 71.540000000000006 110.898 179.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.536 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.0 pp -85.14 -16.59 39.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 71.140000000000001 110.901 179.896 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.536 HG23 ' CD1' ' A' ' 6' ' ' LEU . 99.9 t -114.05 -57.76 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 63.409999999999997 111.134 179.843 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.631 HG11 ' HB2' ' A' ' 17' ' ' SER . 73.1 t -66.25 -58.81 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.111 -0.495 . . . . 65.019999999999996 111.107 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -76.47 -26.16 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 71.439999999999998 111.158 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.68 -18.97 57.69 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.75 -0.738 . . . . 75.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -91.94 -29.28 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.821 0.344 . . . . 61.310000000000002 111.112 179.98 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.37 -26.65 0.2 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.723 -0.751 . . . . 73.299999999999997 112.467 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.63 81.43 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 73.230000000000004 112.525 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.8 t -60.92 -39.65 82.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.812 0.339 . . . . 74.349999999999994 111.115 -179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.73 18.69 11.25 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.682 -0.771 . . . . 55.009999999999998 112.488 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.526 ' O ' HG23 ' A' ' 19' ' ' VAL . 0.4 OUTLIER -109.0 -46.96 3.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.795 0.331 . . . . 71.140000000000001 110.893 -179.951 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.631 ' HB2' HG11 ' A' ' 8' ' ' VAL . 0.3 OUTLIER -64.19 -24.47 67.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 40.119999999999997 110.861 -179.906 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -54.81 -26.72 36.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 73.120000000000005 110.868 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 16' ' ' LYS . 96.7 t -51.64 -29.94 10.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.399999999999999 111.122 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 27.7 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.159 -0.473 . . . . 74.530000000000001 110.899 -179.995 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 ttp . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.852 0.358 . . . . 71.150000000000006 110.841 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.0 t -116.55 -23.83 8.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.239 -0.437 . . . . 65.209999999999994 111.153 -179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -177.5 -66.21 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 74.310000000000002 110.905 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.86 -22.12 11.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 63.119999999999997 110.946 -179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -61.04 -18.83 59.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 74.319999999999993 110.901 179.877 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.7 pp -82.56 -12.78 57.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.215 -0.448 . . . . 55.100000000000001 110.891 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.8 t -114.12 -56.31 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.049999999999997 111.096 179.843 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' A' ' 17' ' ' SER . 60.1 t -66.24 -58.67 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 75.25 111.093 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.29 -27.56 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 74.319999999999993 111.157 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.13 -18.96 56.39 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.71 -0.757 . . . . 54.229999999999997 112.501 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -89.98 -42.2 11.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.852 0.358 . . . . 71.209999999999994 111.084 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.06 -44.7 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 73.109999999999999 112.513 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.35 77.02 0.82 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.684 -0.769 . . . . 75.420000000000002 112.465 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.11 -50.0 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.891 0.377 . . . . 70.239999999999995 111.127 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.34 20.22 6.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.726 -0.75 . . . . 61.420000000000002 112.45 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.586 ' O ' HG23 ' A' ' 19' ' ' VAL . 27.2 mmmt -95.17 -51.7 4.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.761 0.315 . . . . 71.200000000000003 110.882 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.542 ' HB2' HG21 ' A' ' 8' ' ' VAL . 0.4 OUTLIER -59.85 -22.38 62.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 72.310000000000002 110.857 -179.917 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.5 m80 -54.46 -27.05 34.78 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 64.439999999999998 110.863 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 16' ' ' LYS . 93.0 t -51.51 -30.2 10.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 62.43 111.122 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 81.5 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.184 -0.462 . . . . 60.119999999999997 110.876 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.4 tpp . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 61.119999999999997 110.833 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.2 t -114.96 -23.94 8.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 61.299999999999997 111.158 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -178.05 -65.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 75.409999999999997 110.924 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -110.92 -22.13 11.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.483 . . . . 73.319999999999993 110.935 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 16.3 mttt -61.86 -17.6 57.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 73.409999999999997 110.907 179.902 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.51 ' CD1' HG23 ' A' ' 7' ' ' VAL . 2.3 pp -81.4 -15.56 54.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 52.32 110.87 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.51 HG23 ' CD1' ' A' ' 6' ' ' LEU . 92.2 t -113.63 -56.3 4.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.433 . . . . 73.510000000000005 111.118 179.879 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 91.3 t -63.5 -55.95 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 50.009999999999998 111.13 179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 21.2 t -83.46 -27.22 7.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 70.409999999999997 111.143 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -19.08 63.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.69 -0.766 . . . . 75.340000000000003 112.456 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -92.16 -42.95 9.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 73.019999999999996 111.089 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -157.81 -66.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.741 -0.743 . . . . 74.150000000000006 112.485 -179.937 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 129.0 69.48 0.12 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.728 -0.749 . . . . 65.310000000000002 112.464 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.6 t -71.79 -58.66 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.822 0.344 . . . . 74.409999999999997 111.125 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.11 31.01 2.35 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 75.299999999999997 112.446 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.51 ' O ' HG23 ' A' ' 19' ' ' VAL . 28.7 mmmt -99.95 -51.3 3.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.808 0.337 . . . . 72.140000000000001 110.905 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -60.23 -20.52 59.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 75.030000000000001 110.876 -179.902 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 1.1 m80 -53.21 -28.2 25.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 75.510000000000005 110.883 179.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 16' ' ' LYS . 99.6 t -51.4 -30.28 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 41.109999999999999 111.139 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 63.2 m95 . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 71.420000000000002 110.854 179.985 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.3 tpt . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.852 0.358 . . . . 42.340000000000003 110.873 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.432 HG22 ' HD3' ' A' ' 5' ' ' LYS . 13.8 t -119.4 -30.41 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 72.439999999999998 111.178 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -169.08 -65.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 70.129999999999995 110.911 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -109.97 -21.33 12.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.107 -0.497 . . . . 60.340000000000003 110.917 -179.886 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.432 ' HD3' HG22 ' A' ' 2' ' ' THR . 33.8 mtpt -61.31 -17.74 55.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.162 -0.472 . . . . 74.239999999999995 110.866 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.434 HD12 HG23 ' A' ' 7' ' ' VAL . 1.0 OUTLIER -90.98 -18.74 24.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 33.149999999999999 110.909 179.909 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.434 HG23 HD12 ' A' ' 6' ' ' LEU . 79.7 t -108.6 -72.49 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 72.549999999999997 111.092 179.865 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 16' ' ' LYS . 90.5 t -56.97 -49.65 78.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 72.209999999999994 111.127 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 20.0 t -88.0 -24.93 6.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 72.519999999999996 111.121 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -73.6 -19.84 79.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 43.219999999999999 112.491 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -87.34 -32.98 19.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.839 0.352 . . . . 73.439999999999998 111.128 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.37 -44.14 0.21 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.758 -0.734 . . . . 63.119999999999997 112.508 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 131.94 85.05 0.29 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.715 -0.755 . . . . 52.310000000000002 112.493 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.468 ' HB ' HG13 ' A' ' 8' ' ' VAL . 21.9 t -79.09 -39.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.839 0.352 . . . . 75.319999999999993 111.094 -179.96 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.49 5.92 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.749 -0.739 . . . . 53.140000000000001 112.55 -179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.489 ' HB2' HG11 ' A' ' 8' ' ' VAL . 30.9 mmmt -86.21 -48.01 8.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.723 0.297 . . . . 75.549999999999997 110.854 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 9.4 t -52.21 -30.65 28.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 74.420000000000002 110.842 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -54.54 -28.46 45.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 72.450000000000003 110.861 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.2 t -75.76 -50.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 63.100000000000001 111.154 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.17 -0.468 . . . . 63.509999999999998 110.969 179.905 . . . . . . . . 0 0 . 1 stop_ save_